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Abstract
Compartmental models which yield linear ordinary differential equations (ODEs) provide common tools for pharma-
cokinetics (PK) analysis, with exact solutions for drug levels or concentrations readily obtainable for low-dimensional
compartment models. Exact solutions enable valuable insights and further analysis of these systems. Transit compartment
models are a popular semi-mechanistic approach for generalising simple PK models to allow for delayed kinetics, but
computing exact solutions for multi-dosing inputs to transit compartment systems leading to different final compartments is
nontrivial. Here, we find exact solutions for drug levels as functions of time throughout a linear transit compartment
cascade followed by an absorption compartment and a central blood compartment, for the general case of n transit
compartments and M equi-bolus doses to the first compartment. We further show the utility of exact solutions to PK ODE
models in finding constraints on equi-dosing regimen parameters imposed by a prescribed therapeutic range. This leads to
the construction of equi-dosing regimen regions (EDRRs), providing new, novel visualisations which summarise the safe
and effective dosing parameter space. EDRRs are computed for classical and transit compartment models with two- and
three-dimensional parameter spaces, and are proposed as useful graphical tools for informing drug dosing regimen design.
Keywords Mathematical pharmacology  Pharmacokinetics  Compartment models  Differential equations 
Transit compartments  Regimen design
Introduction
Mathematical models for the absorption, distribution and
elimination of drugs are common in the pharmacokinetics
(PK) literature. Typically, a drug’s route through the body
to its pharmacological effect site is modelled as a number
of compartments, with transfer between compartments
being governed by pharmacokinetic rate laws. It is com-
mon to consider only one or two compartments, with linear
pharmacokinetics, resulting in low-dimensional linear
ordinary differential equation (ODE) systems. However,
such models are not sufficient to capture delay-type effects,
whereby some time passes before the drug appears at
measurable levels in the systemic circulation [44]. If a
significant ‘‘drug absorption delay’’ [44, 46] is observed,
then a lag-time is sometimes introduced into solutions to
the simple models to account for the delay, while avoiding
any mechanistic considerations of the underlying delay
roaaataaat esses. This simple approach may be used to
paramaterise a system delay, but it is known that absorp-
tion delay is a complex process that is not switch-like. As
such, lag-time models can give a poor characterisation of
absorption-phase PK.
Transit compartment models have been proposed to
capture delay effects in PK time courses, through a semi-
mechanistic approach of increasing the number of com-
partments through which the drug is transferred en route to
the central compartaament (blood) [26, 27, 32, 33, 44, 46,
47]. The development of ‘‘full’’ or accurate mechanistic
physiologically-based PK models requires much
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experimental data and knowledge which may be unavail-
able. For systems exhibiting delays, transit compartment
models therefore represent a physiologically plausible and
mathematically practical alternative to the change-point
approach of lag-time models.
While transit compartment models add additional com-
plexity beyond one- or two-compartment models, their
outputs in response to a single bolus dose to the first
compartment may be derived analytically in certain cases.
An analytical solution permits relatively straightforward
approaches to both sensitivity analysis (particularly when
varying the number of compartments) and model fitting. In
[44], the response to a bolus dose is considered for an n-
transit compartment model with an additional ‘‘absorption
compartment’’ between transit compartment n and the
central circulation. An analytical solution for the drug
concentration in the nth transit compartment is presented,
and used as an input to the absorption compartment ODE,
together with the Stirling approximation, to transform a
discrete optimisation problem to a continuous one for the
purpose of data fitting. The analysis and parameter esti-
mation is limited to the case of single bolus dose, and exact
solutions are not found for the absorption and central
compartments. Further mathematical properties for transit
compartment models in pharmacodynamics are presented
in [55].
Drug dosing regimens often use multi-dosing treat-
ments, whereby a regular dose is given at regular specified
dosing intervals. For intravenous (IV) or oral administra-
tion of a drug, the analysis of a one- or two-compartment
model with periodic bolus input yields analytical solutions
for the drug level in the central compartment (e.g.
[11, 24, 43, 45]). Time courses of drug level (or concen-
tration) simulations show transient and steady-state (peri-
odic) profiles which may then be compared with minimum
effective and maximum safe levels which define a thera-
peutic window. We will introduce the idea of an equi-
dosing regimen region of (dose,interval)-space, which
gives a guide for selecting therapeutic equi-dosing
regimens.
Given that it is accepted that drug absorption delay may
be a significant pharmacokinetic effect, analysis of transit
compartment models, incorporating multi-dose inputs,
appears to be a valuable pursuit. Some attention has been
paid to this problem in the PK literature. Shen et al. [46]
extend the work of [44] to derive a solution to the multi-
dose problem at the nth transit compartment using the
method of superposition. However, the challenge remains
to solve for the drug level in the central compartment
exactly, and to use this result as a platform for further
analysis, including design of safe dosing regimens.
In this paper, we present new mathematical and graph-
ical results which both generalise transit compartment PK
models and summarise dosing regimen constraints given by
therapeutic ranges imposed on these models. In ‘Methods:
multi-dosing models with and without transit compart-
ments—formulation’, we formulate linear ordinary differ-
ential equation (ODE) models for one-compartment, two-
compartment and transit compartment pharmacokinetics,
extending the work of [44] to consider drug level in the
central compartment. In ‘Analytical solutions for equi-
dosing regimens’, we review standard analytical results for
multi-bolus and multi-infusion dosing, and derive a new
exact solution for the transit compartment model with
general number of compartments and doses. This new
generalised solution and its improvement over existing
models comprise our first main contribution. In ‘Results:
equi-dosing time courses’, we present simulations and data
fitting using the new analytical solutions, illustrating their
predictive capability, and highlighting the error between
the new exact solution and Stirling approximation solution
of [44] for a single bolus dose. In ‘Results: equi-dosing
regimen regions’, we present our second main contribution,
namely the new concept of equi-dosing regimen regions
(EDRRs), which provide a novel visualisation to sum-
marise constraints on dosing regimen parameters. We
conclude in ‘Discussion’ with a discussion of our main
results, highlighting our contributions to the PK and
mathematical modelling literature.
Methods: multi-dosing models
with and without transit compartments—
formulation
General compartmental model schematic
We use a compartmental approach to model a drug’s route
from administration to the systemic circulation. Ultimately,
the systemic circulation is treated as the final compartment
in a cascade, hereafter referred to as the central compart-
ment. The central compartment drug concentration (the
drug amount per volume of distribution) is responsible for
responses at drug effect sites [45], and we consider the drug
level ac as the output in each of our models.
For intranvenous (IV) dosing, the drug immediately
appears in the central compartment upon administration.
We will refer to the corresponding model as a single-
compartment or one-compartment model (Fig. 1, model
(M1)). The amount of drug in the central compartment (the
‘‘drug level’’) in this model is governed by an ordinary
differential equation (ODE) which describes linear phar-
macokinetics, whereby the drug is eliminated from the
compartment as a first order process with elimination rate
constant ke. A two-compartment model (Fig. 1, model
(M2)) in which drug appears in the central compartment
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via an absorption compartment is often used to model oral
dosing [43, 45], where the absorption compartment is
representative of the gastrointestinal (GI) tract. In response
to a bolus dose input, the central compartment drug level ac
in (M2) is both delayed and smoothed in comparison with
the absorption compartment level ab. In order to model a
more pronounced delay by way of a semi-mechanistic
compartmental schematic, we consider a transit compart-
ment cascade feeding the absorption compartment, as in
[44] (Fig. 1, model (Mt)). We note that such a modelling
approach corresponds to the so-called linear chain trick
[23].
Dosing regimen inputs
Dosing patterns in therapeutics often consist of multi-
dosing treatments, whereby doses are administered peri-
odically [11, 43, 45, 46]. Models for multi-dosing are
typically analysed under the assumption of equi-dosing,
whereby both the dose D0 and dosing interval (time
between doses) T are constants. In this case, the couple
ðT;D0Þ constitutes the dosing regimen. Here we principally
investigate equi-dosing regimens in which the input is a
fixed bolus dose administered periodically to the central,
absorption or first transit compartment (see Fig. 2, regimen
(Beq)). We also consider a simple perturbation to this
regimen, where a loading dose DL (greater than D0) is
administered at t ¼ 0, followed by equi-dosing (Fig. 2,
regimen (BeqL)). This regimen is common in practice,
such that a loading dose helps to achieve therapeutic drug
levels rapidly, while the subsequent equi-dosing maintains
therapeutic levels [45].
We further consider the case of equi-infusion dosing,
whereby for model (M1), the input is periodic constant
infusions of drug to the central compartment, over fixed
‘‘on’’ time intervals, separated by fixed ‘‘off’’ intervals
(Fig. 2, regimen (Ieq)).
Model assumptions and considerations
Transit compartment models (TCMs) for PK typically take
the drug amounts in each compartment (ai for i ¼ 1; . . .; n,
ab and ac in Fig. 1) as state variables (see, e.g.,
[26, 44, 46]). The bioavailability factor F, which is the
fraction of drug dose ultimately absorbed into the systemic
circulation, is an important consideration. Existing TCM
models and simpler models introduce this ‘‘correction’’
factor at different points in the cascade
[23, 26, 34, 43, 44, 46]. Here we follow [23, 43] in intro-
ducing the factor immediately, such that the first com-
partment in the cascade is fed by the effective dose
(F  dose).
We consider equi-dosing regimens for both IV infusion
and n-transit compartment cascades, to allow analysis of
drug level time course features in general. Together with
prescribed therapeutic ranges, our analysis will indicate
regions of equi-dosing regimen parameter space which
give safe and effective treatments at steady-state. A ther-
apeutic range is typically defined by minimum effective
and maximum safe drug concentrations in the central
compartment. For a given drug amount ac, the corre-
sponding drug concentration Cc is given by ac=V , where V
is the calculated volume of the central compartment
[25, 43, 45]. Therefore, for a fixed, known volume V, we
can state a corresponding therapeutic range in terms of
drug amounts, requiring
Dme\ac\DMS; ð2:1Þ
where Dme and DMS are the minimum drug level for ther-
apeutic effect and maximum safe drug level respectively.
Fig. 1 Compartmental model schematics. (M1) Single-compartment
model—the input dose immediately appears in the central compart-
ment, in amount ac. (M2) Two-compartment model—the input dose
first appears in an absorption compartment, in amount ab. From here,
it is transferred to the central compartment, in which the amount is ac.
Transfer from absorption to central compartment is a first order
process, with rate constant ka (we consider ka[ ke [45])—and k 6¼
ke; ka [44]. (Mt) Transit-compartment model—the input dose first
appears in the first of n transit compartments, which contain the
amounts a1, a2; . . .; an. Drug is transferred through the cascade of n
transit compartments, as first order process with rate constant k for
each compartment. From transit compartment n, drug is transferred to
the absorption compartment. For all three models, the (first order)
elimination rate constant is ke
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For the transit compartment model, the transit cascade
prior to the absoprtion compartment consists of n com-
partments, each with an elimination rate k. The mean
transit time (MTT) for this cascade is given by (see [44])
MTT ¼ n
k
: ð2:2Þ
Ordinary differential equation formulation
For a multi-dosing regimen, the problem can be stated as
an initial value problem (IVP) for the state variables (e.g. ai
for i ¼ 1; . . .; n, ab and ac for model (Mt)) with impulsive
drug inputs to the first compartment described by a dosing-
rate forcing function comprising Dirac delta functions for
discrete impulses (as in [26, 34]).
Firstly, the IVPs we consider for single-compartment IV
multi-dosing and two-compartment oral multi-dosing are
summarised in Table 1. For equi-bolus dosing with M
doses D0 at time intervals T starting at t ¼ 0 (regimen
(Beq)), the input rate to the first compartment is
gBðtÞ ¼
XM
j¼1
FD0dðt  ðj 1ÞTÞ: ð2:3Þ
If the first bolus dose is replaced with a larger loading dose
DL (regimen (BeqL)), then the forcing rate function is
gBLðtÞ ¼ FDLdðtÞ þ
XM
j¼2
FD0dðt  ðj 1ÞTÞ: ð2:4Þ
For equi-infusion dosing (regimen Ieq) with infusion rate
kin, infusion ‘‘on’’ duration T, infusion ‘‘off’’ duration tf ,
and M infusions, the forcing rate function is
gIðtÞ ¼ Fkin
XM
j¼1

Hðt  ðj 1ÞTÞ  Hðt  ðj 1ÞT  tf Þ

;
ð2:5Þ
where H is the Heaviside function.
We will consider solutions to the IVPs given in Table 1
in constructing the associated equi-dosing regimen regions.
Beyond these relatively simple models, our analysis
extends to the n-transit compartment model with input into
the first transit compartment (model (Mt)). The governing
Fig. 2 Dosing regimen input schematics. (B1) Single bolus dose D0
(measured in mg) administered at time t ¼ 0. (Beq) Equi-bolus
dosing, with a bolus dose D0 mg administered at time t ¼ 0, and again
at times t ¼ T ; 2T ; 3T , etc. The dosing interval T is typically
measured in hours. (BeqL) Equi-bolus dosing (D0;T) with an initial
loading dose DL administered at time t ¼ 0. (I1) Constant infusion,
with drug infused into central compartment, starting at time t ¼ 0, at a
rate kin (mg h
1). (Ieq) Equi-infusion dosing, with drug infused into
central compartment at a rate kin, periodically with period T. Each
dosing interval infusion ‘‘on’’ for duration tf , then infusion ‘‘off’’ for
duration ðT  tf Þ
Journal of Pharmacokinetics and Pharmacodynamics
123
equations consist of ðnþ 2Þ ODEs, which may be written
in matrix form as
d
dt
x ¼ Bxþ g; xð0Þ ¼ 0; ð2:6aÞ
where
x ¼
a1ðtÞ
a2ðtÞ
..
.
..
.
anðtÞ
abðtÞ
acðtÞ
0
BBBBBBBBBBBB@
1
CCCCCCCCCCCCA
; B ¼
k
k  k
k  k
. .
. . .
.
k  k
k  ka
ka  ke
0
BBBBBBBBBBB@
1
CCCCCCCCCCCA
;
g ¼
g1ðtÞ
0
..
.
..
.
0
0
0
0
BBBBBBBBBBBB@
1
CCCCCCCCCCCCA
;
ð2:6bÞ
and
g1ðtÞ ¼
FD0dðtÞ for regimen (B1)
gBðtÞ for regimen (Beq)
gBLðtÞ for regimen (BeqL)
8
><
>:
; ð2:6cÞ
where d is the Dirac delta function.
For all cases, the solution to the IVP consists of all state
variables as functions of time. The primary state variable of
interest is the central circulation drug level acðtÞ.
Analytical solutions for equi-dosing
regimens
Here we present exact solutions for central compartment
drug levels under a variety of equi-dosing regimens. Sin-
gle-compartment and two-compartment model solutions
are included for comparison with transit compartment
model (TCM) solutions, and to aid the construction of equi-
dosing regimen regions in ‘Results: equi-dosing regimen
regions’. The exact TCM solutions represent an improve-
ment on existing approximate solutions [44].
Exact solutions for one-compartment and two-
compartment models with equi-dosing
In Table 2, we list exact solutions for drug level in the
central compartment acðtÞ for one-compartment and two-
compartment model IVPs formulated in Table 1, under
equi-dosing inputs given by Fig. 2 and Eqs. (2.3)–(2.5).
These include well-known solutions (e.g., [6, 19, 45]); for
comparison with the TCM solution, their derivations may
be found in detail in Appendix 1. Throughout, H is the
Heaviside function, and
tj ¼ t  ðj 1ÞT ¼ time since jth dose: ð3:14Þ
Solutions may be written compactly without summation
notation by considering, for example, the central com-
partment drug level after theMth dose, aMc ðtMÞ. The steady-
state (T-periodic) drug level function is denoted a1c ðt1Þ,
where t1 is the time since the start of the dosing interval.
Table 1 Initial value problems (IVPs) of interest for single- and two-
compartment models
Model Input IVP
M1 Beq
dac
dt
¼ keac þ gBðtÞ;
acð0Þ ¼ 0:
M1 BeqL
dac
dt
¼ keac þ gBLðtÞ;
acð0Þ ¼ 0:
M1 Ieq
dac
dt
¼ keac þ gIðtÞ;
acð0Þ ¼ 0:
M2 Beq
dab
dt
¼ kaab þ gBðtÞ;
dac
dt
¼ kaab  keac;
abð0Þ ¼ acð0Þ ¼ 0:
M2 BeqL
dab
dt
¼ kaab þ gBLðtÞ;
dac
dt
¼ kaab  keac;
abð0Þ ¼ acð0Þ ¼ 0:
Here, d is the Dirac delta function, M is the number of doses given,
and T is the dosing interval for bolus doses. Model and Input labels
refer to Figs. 1 and 2
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Exact solution for transit compartment model
with equi-bolus dosing
More generally, the transit compartment model (Mt) com-
prises a multi-compartment oral absorption process, and the
ODEs may be written in matrix form as in (2.6). We consider
equi-bolus dosing, i.e. forcing input (Beq), so that g1ðtÞ ¼
gBðtÞ. The exact solution may be written using the matrix
exponential [9, 27], or by using Laplace Transforms (Ap-
pendix 1.4). For the transit compartments, we find that
aiðtÞ ¼ FD0k
i1
ði 1Þ!
XM
j¼1
HðtjÞti1j ektj ; i ¼ 1; . . .; n;
ð3:15Þ
where tj ¼ t  ðj 1ÞT . We note that this result is equiv-
alent to the multi-dose analytical result of Shen et al [46]
which was derived via superposition arguments, to be used
as an input to their central compartment module, and also
to the Savic single-dose solution [44] if M ¼ 1. We now
extend our calculations to establish solutions for the
absorption and central compartment drug levels, which in
effect gives a general, analytical multi-dose solution to the
Savic problem [44]. The solution for the absorption com-
partment (see Appendix 1.4) is
abðtÞ ¼ FD0ðn 1Þ!
k
k  ka
 nXM
j¼1
HðtjÞekatj c

n; ðk  kaÞtj

;
ð3:16Þ
where c is the lower incomplete gamma function, defined
by (for positive integer n, see [3])
Table 2 Exact solutions to pertinent single-compartment and two-compartment models under equi-dosing regimen inputs
Singl-compartment IV equi-bolus dosing (M1,Beq):
acðtÞ ¼ FD0
PM
j¼1 H

tjÞeketj ; (3.1)
aMc ðtMÞ ¼ FD0
1 eMkeT
1 ekeT
 
eketM ; for 0 tM\T ; (3.2)
a1c ðt1Þ ¼
FD0
1 ekeT
 
eket1 ; for 0 t1\T : (3.3)
Single-compartment IV equi-bolus dosing with loading dose (M1,BeqL), with a1c ðt1Þ given by ():
acðtÞ ¼ F D0
PM
j¼1 H

tjÞeketj
 	
þ ðDL  D0Þeket
n o
; (3.4)
aMc ðtMÞ ¼ F D0
1 eMkeT
1 ekeT
 
eketM þ ðDL  D0ÞekeðtMþðM1ÞTÞ

 
: (3.5)
Single-compartment IV equi-infusion dosing (M1,Ieq):
acðtÞ ¼ Fkin
ke
XM
j¼1
HðtjÞð1 eketjÞ  Hðtj  tf Þð1 ekeðtjtf ÞÞ; (3.6)
aMc ðtMÞ ¼
Fkin
ke
ð1 eketM Þ  HðtM  tf Þð1 ekeðtMtf ÞÞ þ ðeketf  1Þ e
MkeT  ekeT
ekeT  1
 
eketM

 
: (3.7)
a1c ðt1Þ ¼
Fkin
ke
1 e
ketf  ekeT
1 ekeT e
ket1  Hðt1  tf Þð1 ekeðt1tf ÞÞ

 
; for 0 t1\T : (3.8)
Two-compartment oral equi-bolus dosing (M2,Beq):
acðtÞ ¼ ka
ke  ka FD0
XM
j¼1
H

tjÞ ekatj  eketj
 
; (3.9)
aMc ðtMÞ ¼
ka
ke  ka FD0
1 eMkaT
1 ekaT
 
ekatM  1 e
MkeT
1 ekeT
 
eketM
 
; (3.10)
a1c ðt1Þ ¼
ka
ke  ka FD0
ekat1
1 ekaT 
eket1
1 ekeT
 
: (3.1)
Two-compartment oral equi-bolus dosing with loading dose (M2,BeqL), with a1c ðt1Þ given by ():
acðtÞ ¼ ka
ke  ka F D0
XM
j¼1
H

tjÞ ekatj  eketj
 þ ðDL  D0Þ ekat  eket
 
( )
; (3.12)
aMc ðtMÞ ¼
kaF
ke  ka
n
D0
1 eMkaT
1 ekaT
 
ekatM  1 e
MkeT
1 ekeT
 
eketM
 
þ ðDL  D0Þ ekaðtMþðM1ÞTÞ  ekeðtMþðM1ÞTÞ
 o
:
(3.13)
Models and dosing inputs are as in Table 1, H is the Heaviside function, and tj is given by (3.14)
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cðn; tÞ ¼
Z t
0
xn1ex dx ¼ ðn 1Þ! 1 et
Xn1
p¼0
tp
p!
 !
:
ð3:17Þ
Finally, the drug level in the central compartment (the
primary output of interest), acðtÞ, is given by
(Appendix 1.4):
acðtÞ ¼ FD0k
nka
ðn 1Þ!ðke  kaÞ
XM
j¼1
H tj
  ekatj
ðk  kaÞn c

n; ðk  kaÞtj


 e
ketj
ðk  keÞn c

n; ðk  keÞtj

:
ð3:18Þ
We next seek the steady-state solutions, as we have for the
one- and two-compartment problems.
Steady-state behaviour
The derivation of the steady-state solution is more involved
than for the earlier models (see Appendix 1.4.1). For the
transit compartments, we find that
a1i ðt1Þ ¼
Xi1
p¼0
a1ipð0Þ
p!
ðkt1Þp
 !
ekt1 ; for i ¼ 1; . . .; n:
ð3:19Þ
The coefficients aið0Þ (the steady-state dosing interval
initial values) may be found using
a11 ð0Þ ¼
FD0
1 e/ : ð3:20Þ
together with the recurrence relation (for i ¼ 2; . . .; n)
aið0Þ ¼b a
1
i1ð0Þ
1!
/þ a
1
i2ð0Þ
2!
/2 þ a
1
i3ð0Þ
3!
/3

þ    þ a
1
1 ð0Þ
ði 1Þ! /
i1

¼ b
Xi1
p¼1
a1ipð0Þ
p!
/p;
ð3:21Þ
where
/ ¼ kT ; and b ¼ e
/
1 e/ : ð3:22Þ
Computationally, we may use this recurrence relation.
Further, a closed form expression for a1i ð0Þ is found (see
Appendix 1.4.1):
a1i ð0Þ ¼
FD0
1 e/
/i1
ði 1Þ!
Xi1
p¼0
p!Sði 1; pÞbp;
for i ¼ 1; . . .; n;
ð3:23Þ
where S is the Stirling number of the second kind [40],
given by
Sðn; qÞ ¼ 1
q!
Xq
p¼0
ð1Þp q
p
 
ðq pÞn;
where
q
p
 
¼ q!
p!ðq pÞ! is the binomial coefficient;
ð3:24Þ
and taking Sð0; 0Þ ¼ 1. For the absorption compartment,
we find
a1b ðt1Þ ¼ a1b ð0Þ þ
Xn
p¼1
a1p ð0Þ
ðn pÞ!
k
k  ka
 npþ1"
cðn pþ 1; ðk  kaÞt1Þ
#
ekat1 ;
ð3:25Þ
where
a1b ð0Þ ¼ ba
Xn
p¼1
a1p ð0Þ
ðn pÞ!
k
k  ka
 npþ1
cðn pþ 1; ðk  kaÞTÞ;
ð3:26Þ
and
ba ¼
ekaT
1 ekaT : ð3:27Þ
Finally, and ultimately, the steady-state profile in the
central compartment is given by
a1c ðt1Þ¼ a1c ð0Þeket1 þ
ka
ka ke

(
a1b ð0Þðeket1  ekat1Þ þ
Xn
p¼1
a1p ð0Þ
ðn pÞ!
k
k ke
 npþ1
eket1
"
cðn pþ 1; ðk keÞt1Þ
k
k ka
 npþ1
ekat1 cðn pþ 1; ðk kaÞt1Þ
#)
;
ð3:28Þ
where
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a1c ð0Þ ¼ bc 
(
a1b ð0ÞðekeT  ekaTÞ þ
Xn
p¼1
a1p ð0Þ
ðn pÞ!
k
k  ke
 npþ1
ekeT cðn pþ 1; ðk  keÞTÞ 
"
k
k  ka
 npþ1
ekaT cðn pþ 1; ðk  kaÞTÞ
#)
;
ð3:29Þ
and
bc ¼
ka
ðka  keÞð1 ekeTÞ : ð3:30Þ
We now have in place new analytical solutions for a gen-
eral M-equi-dose input to an n-transit compartment model
with absorption and central compartments. These solutions
may be used to predict drug level dynamics exactly, rather
than approximately (see (4.5)). Further, the steady-state
solutions may be used to guide safe and effective dosing
regimen design, given a specified therapeutic range.
Computational evaluation of the lower incomplete gamma
function
In order to use the analytical results of the previous sub-
section, a computational method for evaluating the lower
incomplete gamma function is required. The definition
itself (3.17) immediately suggests several approaches for a
given n, including numerical evaluation of the integral for
given t, computation of the truncated exponential sum, and
using symbolic computation to derive an exact expression
for the integral, then evaluating at given t. In fact, more
efficient methods for evaluating this function have received
attention in the mathematical literature, with many
involving series and continued fraction expansions
[1, 2, 17, 41, 50]. In MATLAB, the built-in function
gammainc may be used [35], and is our preferred eval-
uation method due to its accuracy and run time (see
Appendix 1.4.2). In software where such a function is not
avaialble, the following relationship between the lower
incomplete gamma function c and the cumulative distri-
bution function FC for the gamma distribution may be used
( [35]):
cðn; tÞ ¼ CðnÞFCðt; n; 1Þ: ð3:31Þ
Here, n is taken as the shape parameter of the distribution,
and the scale parameter is unity. Furthermore, the log-
gamma function is a built-in function in many software
packages, and the exponentiated log-gamma function is
often used in situations where numerical difficulties may
arise in evaluating the gamma function directly [35].
Hence, a practical approach for evaluating cðn; tÞ is to use
built-in functions to evaluate
cðn; tÞ ¼ elnCðnÞFCðt; n; 1Þ ¼ expðlnCðnÞÞFCðt; n; 1Þ:
ð3:32Þ
The log-gamma function is available in PK analysis
packages and languages including NONMEM [4],
MLXTRAN/MONOLIX [31], PharmML [48], and also in
MATLAB [35] and Excel [37]. Each of these packages also
has the exponential function and cumulative gamma dis-
tribution F available.
Results: equi-dosing time courses
Here, we present simulated time courses of drug levels,
using the analytical solutions given in ‘Analytical solutions
for equi-dosing regimens’. In all cases, we have computed
using MATLAB [35].
IV equi-bolus dosing—one-compartment model
In Fig. 3a, we plot a typical drug level time course for the
IV equi-bolus dosing problem (M1,Beq), which has solu-
tion given by (3.2), and steady-state profile given by (3.3).
The characteristic features of the time courses include jump
discontinuities at t ¼ jT , exponential decay over each
dosing interval, and approach to a periodic steady-state
[45]. Clearly, acceptable dosing regimens would only exist
for certain ðT ;D0Þ choices. Also shown is the continuous
infusion profile given by
acðtÞ ¼ Fkin
ke
ð1 eketÞ; ð4:1Þ
taking kin ¼ D0T (see (A.16)). The dosing interval average
drug level approaches the corresponding infusion steady-
state level, which is apparent from the graph, and from
calculating a1c ½0;T  ¼ F
D0
T
ke
from (3.3) and comparing with
the steady-state of (4.1). Finally, we note that the admin-
istration of a loading dose at time t ¼ 0 may give a treat-
ment that is immediately and always therapeutic, and drug
levels close to the steady-state.
IV equi-infusion dosing
In Fig. 3b, we plot a typical drug level time course for the
IV equi-infusion dosing problem (M1,Ieq), which has
solution given by (3.6), and steady-state profile given
by (3.8). The characteristic features of the time courses
include derivative discontinuities (but continuous drug
levels) at t ¼ jT and t ¼ jT þ tf , exponentially decaying
rise followed by exponential decay over each dosing
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interval, and approach to a periodic steady-state [45].
Again, acceptable dosing regimens would only exist for
certain ðT;D0Þ choices.
Single continuous infusion as limit of IV equi-
bolus dosing
In Fig. 3c, we plot a drug level time course for IV con-
tinuous infusion (4.1) for infusion rate kin, together with an
equi-bolus dosing (M1,Beq) solution (3.2) for which the
dosing rate is D0T ¼ kin with very short dosing interval T. It
is apparent, and intuitively known, that continuous infusion
represents a limit of a corresponding equi-bolus regimen
for high dosing frequency. In Appendix 2.1 we offer a
proof of this result using l’Hopital’s rule.
Oral bolus equi-dosing—two-compartment
model
In Fig. 3d, we plot a typical drug level time course for the
oral equi-bolus dosing problem (M2,Beq), which has
solution given by (3.10), and steady-state profile given
by (3.11). The characteristic features of the time courses
include derivative discontinuities at t ¼ jT , a two-phase
profile (absorption then elimination) over each dosing
interval, and approach to a periodic steady-state [45]. We
note that the administration of a loading dose at time t ¼ 0
may give a treatment that reaches therapeutic level earlier,
but for which there is still some nonzero waiting time
before the therapeutic level is reached. It is clearly possible
to give a loading dose which ensures that therapeutic drug
level is both reached within the first dosing interval and is
maintained thereafter.
The acðtÞ time course approaches a T-periodic steady-
state profile, which will be non-monotonic for all regimens
(even those for which the time course is monotonic for the
Fig. 3 Drug level time courses. Throughout, we take F ¼ 1. Where
shown, Dme and DMS represent hypothetical minimum effective and
maximum safe levels respectively, giving the therapeutic range
½Dme;DMS. Where shown, the steady-state profile overlays the final
dosing interval for comparison. a IV equi-bolus dosing (M1, Beq),
with and without loading dose. D0=500 mg, T = 12 h,
ke ¼ 0:0692 h1 (taken from [10]). Loading dose (M1,BeqL) has
DL ¼ 800 mg. Continuous infusion at a rate kin ¼ D0T ¼ 41:67 h1 is
also shown. b IV equi-infusion dosing (M1,Ieq) with kin ¼ 41:67 h1,
tf ¼ 3 h, T ¼ 6 h, ke=0.0692 h1. c IV equi-bolus dosing (M1, Beq)
with D0=20.83 mg, T=0.5h, ke ¼ 0:0692h 1, together with contin-
uous infusion with kin ¼ D0T ¼ 41:67 h1. (d) Oral equi-bolus dosing
(M2,Beq) with D0 = 500 mg, T=12h, ke ¼ 0:0692 h1, ka ¼ 0:7 h1.
Loading dose (M2,BeqL) has DL ¼ 800 mg
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early dosing intervals), exhibiting both absorption and
elimination phases. Expressions for the peak drug level and
the peak timing are given in Appendix 2.2. Maximum and
minimum drug levels for a number of models will be used
in ‘Results: equi-dosing regimen regions’ to construct equi-
dosing regimen regions, which give a summary guide for
regimen design.
Transit compartments—smoothed delays, lag
time and data fitting (single-dose)
In Fig. 4, we demonstrate the delaying effect of a train
of transit compartments for a single dose regimen. It is
clear (Fig. 4a) that a delta-function-like bolus dose input to
the first transit compartment effects a ‘‘spread-out bolus’’
dose in later transit compartments. Eventually a spread-out
bolus profile is seen for the final transit compartment,
which becomes the input to the absorption compartment,
centered around t ¼ MTT ¼ nk. As in [44], we consider the
transit compartment cascade delaying the appearance of
bolus dose in the absorption compartment of a standard
two-compartment oral dosing model. We see that (Fig. 4b,
c), for a fixed time lag tlag ¼ MTT taking k ¼ MTTn , the pure
delay (time-lag) profiles (see [45])
alagb ðtÞ ¼
0 0 t tlag
FD0e
kaðttlagÞ t[ tlag


; ð4:2Þ
and
alagc ðtÞ¼
0 0 ttlag
ka
kekaFD0 e
kaðttlagÞ ekeðttlagÞ
 	
t[ tlag
8
<
: ;
ð4:3Þ
are approached by the equivalent transit compartment
approximations for increasing n. Such ‘‘smoothed delay’’
profiles may well capture experimental data better than no-
delay or pure-delay models [44]. Indeed, we find a better fit
to published data for a single dose of the drug gliben-
clamide [44] using a transit compartment model than using
a pure time-lag model (Fig. 5). For the least-squares data
fitting shown in Fig. 5, we use the optimisation function
fminsearch in MATLAB [35], with the objective
function being the sum of squares between data and sim-
ulation at the data points. For each fixed n in turn, and for
the time-lag model (for which tlag is one of the fitted
parameters), the optimisation routine is run for 1000
iterations.
Parameter identifiability
We note that applying optimisation routines to estimate PK
parameters for n ¼ 1 (a single transit compartment) should
be with caution, since in this case, ke is identifiable but k
and ka are unidentifiable. This is readily seen by consid-
ering a single bolus dose to the transit compartment for
cases (i) k ¼ k1 and ka ¼ k2, and (ii) k ¼ k2 and ka ¼ k1,
for rate constants k1 and k2. In both cases, the inflow rate to
Fig. 4 Drug level time courses
for transit compartment model
with a single dose (Mt,B1).
Throughout, we take F ¼ 1, D0
= 500 mg, ke=0.0692 h
1
ka=0.7 h
1 (for hypothetical
drug described in [10]). Here,
tlag ¼ MTT ¼ 3h, and k ¼ MTTn .
a Drug level aiðtÞ for
compartments i ¼ 3; 20; 60; 100
of a cascade with n ¼ 100
transit compartments. b
Absorption compartment level
abðtÞ for cascades with n ¼
3; 20; 60; 100 transit
compartments, with equivalent
time-lag profile for pure delay to
absorption compartment. c
Central compartment level acðtÞ
for cascades with n ¼
3; 20; 60; 100 transit
compartments, with equivalent
time-lag profile for pure delay to
absorption compartment
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the central compartment kaabðtÞ is found from (3.15) to
(3.16) to be
kaabðtÞ ¼ FD0 k1k2
k2  k1 e
k1t  ek2t : ð4:4Þ
The central compartment drug level will be identical for
both cases, hence ka and k are not uniquely identifiable
from the single output acðtÞ. This is a manifestation of the
so-called flip-flop phenomenon for two-compartment
kinetics [45]. The parameter ke is identifiable. An example
computation is shown in Appendix 2.3. For n[ 1 this
phenomenon is avoided, and all parameters are uniquely
identifiable (see Appendix 2.3).
Transit compartments—exact
versus approximate solutions
The original transit compartment schematic presented in
[44] has been key to our analysis. A significant advance in
our work is the development of an analytical solution
which solves the problem exactly. The original single bolus
dose analysis [44] uses exact solutions for each transit
compartment, but employs the Stirling approximation for
the factorial, to solve the following system for the final two
compartments.
dab
dt
¼ FD0k
n
ffiffiffiffiffi
2p
p ðn 1Þn12eðn1Þ
tn1ekt; ð4:5aÞ
dac
dt
¼ kaab  keac; ð4:5bÞ
abð0Þ ¼ acð0Þ ¼ 0: ð4:5cÞ
A comparison between a typical numerical solution of the
approximate model (4.5) and corresponding exact solu-
tions given by (3.16)–(3.18) for a single bolus dose is given
in Fig. 6. It is clear that the new exact solutions provide a
significant improvement in accuracy over the approximate
solutions, particularly for n 4, for which the relative error
in the peak ac value is between 3% and 8.4%.
Transit compartments—equi-dosing
While the published data and modelling in [44] focus on a
single dose, we naturally wish to use such models for
simulating time courses under multi-dosing regimens. The
local maxima and minima in a multi-dosing timecourse
prediction as the system approaches a periodic steady-state
must be considered in regimen design [12]. In Fig. 7, we
show predicted equi-dosing drug levels together with data
used for fitting to a single dose, as in [12]. The approach to
a periodic steady-state is clear in each case. For each
timecourse, we note that the transit compartment profile is
Fig. 5 Drug level time courses for transit compartment model with a
single dose (Mt,B1), with fitting to experimental data for drug
glibenclamide, taken from [44], using WebPlotDigitizer [42], in
response to a 3.5 mg dose. Original data converted from concentra-
tion to drug level using volume of distribution of 3.79l [44]. Central
compartment drug level (mg) versus time (h) is shown. a Time
courses fitting model (Mt,B1) to data for varying number of transit
compartments n. b Sum of squared errors between data and best-fit
simulation for 2 n 15. c Best-fit transit compartment and lag-time
models, together with time course data. For (Mt,B1) model, n ¼ 10
gives best fit, with fitted parameters k ¼ 12:76 h1, ka ¼ 9:11 h1,
ke ¼ 0:96 h1, F ¼ 0:69, and sum of squared errors 0.059. For time-
lag model, fitted parameters are ka ¼ 5:67 h1, ke ¼ 0:92 h1,
tlag ¼ 0:78h and F ¼ 0:63, and sum of squared errors 0.38
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bounded by the pure time delay profile as we approach
steady-state. So using a pure time lag model to fit single
dose data and predict multi-dosing dynamics may overes-
timate the level of fluctuation, which is an important
characteristic considered in regimen design.
In Appendix 2.4, we present further time course simu-
lations illustrating the effect of the transit rate constant on
the smoothed delay through the system.
Results: equi-dosing regimen regions
It is common to consider potential therapeutic protocols
which will give steady-state drug levels within a prescribed
therapeutic range by simulation with multiple dosing reg-
imens and observing whether the steady-state falls within
that therapeutic range [12, 25, 43, 45]. One can approach
dosing regimen design iteratively, simulating in this man-
ner and adjusting base parameters until a theoretically safe
and therapeutic regimen is found [25]. Here we present a
novel and alternative analysis which will capture the con-
straints imposed on the dosing regimen parameters by the
therapeutic range, which is given by
Dme ¼minimum effective level and
DMS ¼maximum safe level:
ð5:1Þ
We propose that equi-dosing regimen regions (EDRRs),
which are regions of the parameter space giving accept-
able regimens, may be used to summarise steady-state
constraints and guide regimen design from the outset of
any investigation.
Two-parameter dosing regimens
Equi-dosing regimen region for IV equi-bolus dosing
For model (M1) with forcing (Beq), we seek constraints on
the two equi-dosing regimen parameters D0 and T such that
the steady-state time course given by (3.3) has
Dme\a1c ðt1Þ\DMS: ð5:2Þ
Now a1c ð0Þ ¼ FD01ekeT and a1c ðTÞ ¼ FD0e
keT
1ekeT , with a
1
c ðt1Þ
decreasing, so we require that
Dme\
FD0e
keT
1 ekeT and
FD0
1 ekeT \DMS;
so that the region of ðT ;D0Þ-space for acceptable dosing
regimens is that corresponding to the inequality constraints
Fig. 6 Difference between exact and approximate solutions for transit
compartment model with single bolus dose. Throughout, we take
ka ¼ 9:11 h1, ke ¼ 0:96 h1, F ¼ 0:69, D0 ¼ 3:5mg, and
MTT ¼ 0:78h, and for each n, we take k ¼ nMTT. a Absorption
compartment drug level - exact (3.16) versus approximate (4.5)
solutions for varying n. b Central compartment drug level—
exact (3.18) versus approximate (4.5) solutions for varying n. c
Relative error made using Stirling approximation of n!. (d) Root mean
squared error (RMSE) and relative error between exact and approx-
imate solution peak values for acðtÞ shown in panel (b)
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Dme
F
ekeT  1  \D0 \ DMS
F
1 ekeT : ð5:3Þ
The upper bounds on T and D0 for the safe and effective
dosing region are given by
T ¼ 1
ke
log
DMS
Dme
 
; D0 ¼ 1
F
ðDMS  DmeÞ: ð5:4Þ
We see in Fig. 8a that the acceptable EDRR for equi-bolus
dosing is given by a petal-shaped region. The two curves
divide the ðT;D0Þ parameter space into four regions; the
three regions other than the EDRR correspond to steady-
state drug levels which are unsafe, sub-therapeutic, or both
unsafe and sub-therapeutic over subintervals of their peri-
odic timecourses. Illustrative drug level time courses are
shown in Fig. 9.
Clearly the EDRR could be used at the outset of any
investigation to guide regimen design, prior to any time
course simulation or experiment.
Equi-dosing regimen region for oral equi-bolus dosing
For model (M2) with forcing (Beq), we consider the
steady-state solution (3.11). It is straightforward to show
(Appendix 2.2) that the minimum and maximum levels
a1c;min, a
1
c;max, and peak time t

1 are given by
a1c;min¼a1c ð0Þ ¼
ka
kekaFD0
1
1ekaT 
1
1ekeT

 
;
ð5:5aÞ
t1 ¼
1
ka  ke log
ka
ke
1 ekeT
1 ekaT
 
; ð5:5bÞ
Fig. 7 Equi-dosing drug level acðtÞ time courses for transit compart-
ment model (Mt,Beq). a Simulated time course (Mt,B1) for n ¼ 10
transit compartments with MTT ¼ 3h. Here, F ¼ 1, ke=0.0692 h1
ka=0.7 h
1 (for hypothetical drug described in [10]). Equi-dosing
regimen has D0 = 500 mg, T=8h. Also shown is equivalent pure time
lag result. b Simulated time course for parameters fitted to Savic
single dose data [44] for glibenclamide and (Mt,B1) model, as in
Fig. 5. Equi-dosing regimen has D0 = 3.5 mg, T=3h. Also shown are
equivalent pure time lag result, and data points used for fitting. c
Simulated time course for parameters fitted to a Savic single dose
time course (for a different individual) digitised from [44] for
glibenclamide and (Mt,B1) model. Equi-dosing regimen has D0 =
3.5 mg, T=3h. Also shown are equivalent pure time lag result, and
data points used for fitting. For (Mt,B1) model, n ¼ 10 gives best fit,
with fitted parameters k ¼ 17:59 h1, ka ¼ 0:87 h1, ke ¼ 0:48 h1,
F ¼ 0:37
(a) (b)
Fig. 8 The two-dimensional equi-dosing regimen regions (EDRRs, the shaded, petal-shaped regions) for a IV equi-bolus dosing, and b oral equi-
bolus dosing. Functions flo and fhi are given in (5.6)
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Fig. 9 Equi-dosing regimen region (EDRR) for IV dosing with
F ¼ 1, ke ¼ 0:0692h1, and hypothetical minimum effective and
maximum safe drug levels Dme ¼ 300 mg and DMS ¼ 1000 mg.
Sample time courses acðtÞ for four ðT ;D0Þ regimens are shown,
illustrating four different possibilities for the steady-state drug level:
(i) unsafe (toxic, overshooting therapeutic range), (ii) acceptable (safe
and effective, entirely within therapeutic range), (iii) both overshoot-
ing and undershooting therapeutic range, (iv) ineffective (under-
shooting therapeutic range)
Fig. 10 Equi-dosing regimen region (EDRR) for oral dosing with
F ¼ 1, ke=0.0692 h1, ka=0.7 h1, and hypothetical minimum effec-
tive and maximum safe drug levels Dme ¼ 300 mg and
DMS ¼ 1000 mg. Sample time courses acðtÞ for four ðT ;D0Þ regimens
are shown, illustrating four different possibilities for the steady-state
drug level: (i) unsafe (toxic, overshooting therapeutic range), (ii)
acceptable (safe and effective, entirely within therapeutic range), (iii)
both overshooting and undershooting therapeutic range, (iv) ineffec-
tive (undershooting therapeutic range)
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a1c;max ¼ a1c t1
  ¼ FD0 ke
ka
 ke 1 ekaT ke
1 ekeTð Þka
( ) 1
kake
:
ð5:5cÞ
Again requiring that Dme\a1c ðt1Þ\DMS, we find that the
region of ðT ;D0Þ-space for acceptable dosing regimens is
that corresponding to the inequality constraints
Dme
F
ka  ke
ka
ð1 ekeTÞð1 ekaTÞ
ekeT  ekaT

 
|fflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflffl{zfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflffl}
floðTÞ
\ D0 \
DMS
F
ke
ka
 ke 1 ekaT ke
1 ekeTð Þka
( ) 1
keka
|fflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflffl{zfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflffl}
fhiðTÞ
:
ð5:6Þ
We see in Fig. 8b that the acceptable EDRR for oral equi-
bolus dosing is given by another petal-shaped region. The
crossover values D and T are not easily found analyti-
cally as in (5.4) this time; if values are required for these,
they may be found numerically. Again the parameter space
is divided into four regions which correspond to different
Table 3 Summary algorithms for constructing two-parameter ðT ;D0Þ equi-dosing regimen regions
Analytical approach (one- and two-compartment models) Numerical approach for TCM (construct floðTÞ and
fhiðTÞ numerically)
Find expression for max and min values of a1c , namely a
1
c;max and a
1
c;min, in terms of
dosing regimen parameters D0 and T, as in (5.2) and (5.5)
Set therapeutic range constraints Dme\a1c;min and a
1
c;max\DMS
Rearrange constraints into form floðTÞ\D0\fhiðTÞ, as in (5.3) and (5.6)
Plot curves D0 ¼ floðTÞ and D0 ¼ fhiðTÞ. Region bounded by these two curves is the
EDRR
Discretise the ðT ;D0Þ parameter space, i.e. lay down a
grid of points ðTi;D0;jÞ
For each Ti:
For each D0;j:
Use expression for a1c ðt1Þ (3.28) to compute
a1c;max and a
1
c;min numerically
End
floðTiÞ ¼ D0;j such that ja1c;min  Dmej is minimised
fhiðTiÞ ¼ D0;j such that ja1c;max  DMSj is minimised
End
Plot curves D0 ¼ floðTÞ and D0 ¼ fhiðTÞ. Region
bounded by these two curves is the EDRR
(a) (b)
Fig. 11 Equi-dosing regimen region (EDRR) for transit compartment
model with F ¼ 1, ke=0.0692 h1, ka=0.7 h1, and hypothetical
minimum effective and maximum safe drug levels Dme ¼ 300 mg and
DMS ¼ 1000 mg. In both plots, the solid light blue EDRR is that for
standard oral dosing with no transit compartments, and the four
EDRR boundary curves are for transit compartment models with
varying number of transit compartments n. a Varying n with fixed
mean transit time MTT ¼ 4:4 h, so that k ¼ nMTT. b Varying n with
fixed transit rate constant k ¼ 0:45 h1, so that MTT ¼ nk
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safety and effectiveness combinations. A computed EDRR
with illustrative drug level time courses is shown in
Fig. 10.
Equi-dosing regimen region for oral equi-bolus dosing
with n transit compartments
For the transit compartment model (Mt) with forcing (Beq),
we consider the steady-state solution (3.28). Locating
extrema in the time course is no longer viable analytically;
simple inequalities such as in (5.3) and (5.6) cannot be
found. Instead, to construct the EDRR, we discretise the
ðT;D0Þ-space, and compare numerically-found maxima
and minima of acðtÞ with DMS and Dme respectively. The
numerical method for constructing transit compartment
EDRRs is summarised algorithmically and compared with
the analytical approach for the simpler models in Table 3.
In Fig. 11, we show EDRRs for transit compartment
models with varying number of transit compartments n,
while fixing either the transit rate constant or the mean
transit time (which effects the ‘‘smoothed delay’’). In each
case, the EDRR is petal-shaped. Since the smoothed delay
gives a narrower band for the steady-state timecourse than
pure time-lag, the transit compartment EDRRs always
contain the standard oral-dosing EDRR as a subset.
Increasing either the timing of the delay (by decreasing
n with k fixed) or its ‘‘spread’’ (by increasing n with MTT
fixed) results in extension of the EDRR. For safe, conser-
vative dosing regimen design, any regimen within the
standard oral-dosing EDRR can, of course, be chosen.
Three-parameter dosing regimens
While equi-bolus dosing (input (Beq), with parameters T
and D0) is often of interest, we note that the cases of equi-
bolus dosing with loading dose (input (BeqL)) and equi-
infusion dosing (input (Ieq)) are also important clinically
[43]. Appropriate three-dimensional EDRRs for these
three-parameter regimens for IV administration may also
be constructed using the analytical results.
Equi-dosing regimen region for IV equi-bolus dosing
with loading dose
For model (M1) with forcing (BeqL), we seek constraints
on the three equi-dosing regimen parameters D0, T and DL
such that the time course given by (3.4) gives drug level
that is safe and therapeutic immediately and always. The
peak and trough levels are monotonic in time, so the nec-
essary and sufficient constraints are that the steady-state
time course given by (3.3) has
Dme\a1c ðt1Þ\DMS; ð5:7Þ
and also that the drug level for the first dosing interval is
entirely within the therapeutic range, i.e.
Dmee
keT\FDL\DMS: ð5:8Þ
For any given loading dose, the steady-state constraints
require T and DL to be within the petal-shaped two-pa-
rameter EDRR as before. The added constraints (5.8) limit
the dosing interval duration such that
T\
1
ke
log
FDL
Dme
:
Fig. 12 The two-dimensional
equi-dosing regimen region (the
shaded region) for equi-bolus
ðT;D0Þ dosing with fixed
loading dose DL. Due to the
added loading dose
constraints (5.8), the slice is
now a ‘‘chopped petal’’
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Thus, for fixed DL, the two-parameter (T ;D0) dosing reg-
imen region is a ‘‘chopped petal’’ shape, as shown in
Fig. 12. The three-dimensional EDRR is given by the
union of all such chopped petals, with DL ¼ DmeF ekeT as a
boundary surface.
A computed three-parameter EDRR with illustrative
drug level time courses is shown in Fig. 13. The upper
boundary surface projected onto the ðT ;D0Þ plane gives the
two-parameter EDRR for IV dosing (see further visuali-
sation in Appendix 3). Only regimens (b) and (c) are within
the three-parameter EDRR. Regimen (d) gives time course
which is not therapeutic immediately, but it is at steady-
state; it is clear that addition of a larger loading dose as in
(c) gives an acceptable regimen. Practical dosing consid-
erations such as frequency of administration, and thera-
peutic considerations such as drug level fluctuation, dosing
interval averages and safety margins, can lead to specific
dosing protocols [43]. Regimens following such protocols
can easily be found by exploring the EDRR intuitively, for
example, taking into account proximity to EDRR
boundaries.
IV infusion equi-dosing
For model (M1) with forcing (Ieq), we have the three
parameter dosing regimen ðT; kin; tf Þ, and seek constraints
for safe and therapeutic drug levels at steady-state. From
(3.8), since the maximum and minimum drug levels at
steady-state occur at t1 ¼ tf and t1 ¼ 0 respectively, we
readily find that
maxða1c Þ ¼ a1c ðtf Þ ¼
Fkin
k
1 eketf
1 ekeT
 
; ð5:9Þ
and
Fig. 13 Three-dimensional equi-dosing regimen region (EDRR) for
IV dosing with loading dose, with F ¼ 1, ke=0.0692 h1, and
hypothetical minimum effective and maximum safe drug levels
Dme ¼ 300 mg and DMS ¼ 1000 mg. Three ‘‘chopped petal’’ cross
sections are highlighted for illustration: DL ¼ 475 (blue), DL ¼ 650
(red), DL ¼ 825 (green). Sample time courses acðtÞ for four
ðT;D0;DLÞ regimens are shown. Only regimens (b) and (c) are
within the three-parameter EDRR. Regimen (d) gives time course
which is not therapeutic immediately, but it is at steady-state
Fig. 14 The two-dimensional equi-dosing regimen region (the shaded
region) for equi-infusion with fixed tf . The value k

in is given in (5.12)
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minða1c Þ ¼ a1c ðtf Þ ¼
Fkin
k
1 eketf
1 ekeT
 
: ð5:10Þ
The acceptable three-dimensional equi-dosing regimen
region (for tf\T) is therefore given by
Dme
1 ekeT
1 eketf \
Fkin
ke
\DMS
1 ekeT
1 eketf : ð5:11Þ
It is instructive first to consider a two-parameter ðT; kinÞ
EDRR, given fixed infusion off-time tf . We find another
chopped petal two-dimensional region, now as illustrated
in Fig. 14. It is straightforward to show that the cross-over
value of infusion rate is
kin ¼
ke
F
DMS  Dmeeketf
1 eketf
 
: ð5:12Þ
The petal does not extend to the origin in the ðT ; kinÞ-plane;
it is chopped at at T ¼ tf due to the simple constraint that
tf\T .
The three-dimensional EDRR is given by the union of
all such chopped petals as tf varies, bounded by the planes
T ¼ tf and T ¼ tf þ 1ke log
DMS
Dme
. In Fig. 15, we show a
computed three-parameter EDRR for a range of tf values,
with illustrative drug level time courses. It is clear that
dosing regimens can easily be chosen from within the
EDRR. Only regimens (a) and (b) are within the three-
parameter EDRR. Furthermore, systematic, direction-based
regimen perturbations within the EDRR can be made to
affect time course properties such as fluctuation level. The
EDRR is proposed as a useful summary towards dosing
regimen design.
Discussion
We have derived new analytical solutions for a generalised
multi-dose transit compartment model (TCM), extending
the analysis of the popular model in [44]. These solutions
provide a means for analysing and parameterising delayed
drug-level time courses without the need for nonsmooth
time-lag models. The smoothed delay profile may be seen
to give a better fit to experimental data than pure time delay
models. The generalised model allows for simulation of
realistic repeated dosing regimens that have traditionally
been analysed in detail for simpler one- and two-com-
partment models [10, 43, 45]. In this sense, we importantly
bridge the gap between traditional multi-dose analysis and
the time-delay and TCM literature [23, 26–28, 38, 44, 55],
providing a powerful method for capturing delays.
The exact solutions for the multi-dosing TCM will serve
primarily as a tool for PK analysis. Further complexity may
also be added as a future modelling extension by consid-
ering the ‘‘body’’ as a two-compartment schematic
including central and peripheral compartments. Since first-
order transfer is typically considered between these com-
partments [20, 43], the resulting ODE system including the
Fig. 15 Three-dimensional ðT ; tf ;D0Þ equi-dosing regimen region for
multi-infusion, with F ¼ 1, ke=0.21, and hypothetical minimum
effective and maximum safe drug levels Dme ¼ 200 mg and
DMS ¼ 3000 mg. Three ‘‘chopped petal’’ cross sections are
highlighted for illustration: tf ¼ 4 (blue), tf ¼ 2:5 (red), tf ¼ 1
(green). Sample time courses acðtÞ for four regimens are shown.
Only regimens a and b are within the three-parameter EDRR (Color
figure online)
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full transit compartment cascade will be linear. As such, we
expect analytical solutions to be available again, via the
Laplace Transform method. Our new TCM analysis may
also have application beyond PK. For example, signal
transduction dynamics can often be modelled with linear
transit compartment cascades [15, 30, 47, 54]. Recently,
solutions comprising incomplete gamma functions have
been found for linear signal transduction cascades under
different input conditions [5]. We expect that further
analysis of periodic impulsive inputs to such systems will
be valuable.
Drug dosing regimen design is an important considera-
tion in therapeutics, from the stage of drug development
[39] through to personalised regimens [14, 36]. Given PK
parameters, prediction of drug levels based on regimen
parameters is common. With analytical expressions for
drug levels as functions of time, we have shown that
constraints on dosing parameters are readily available at
the outset of any simulation-based study. Furthermore, the
corresponding equi-dosing regimen regions (EDRRs) pro-
vide a novel, clear and succinct summarising visualisation
of the acceptable dosing regimen parameter space, which
may be explored intuitively to design effective and non-
toxic treatments.
Predictive modelling using ODE models for PK is
common, with end-user pharmacologists widely using
exact solutions for low-dimensional compartmental models
via a range of computational tools. Rapid computation of
predicted time courses for multiple dosing regimens has
further been facilitated by the development of used-
friendly simulation packages (e.g. [16, 18, 22]). EDRR
visualisation can easily be achieved through a variety of
computational tools, and we suggest that EDRRs could
easily be incorporated into a number of packages to aid
regimen design studies.
Finally, we remark that the mathematical detail of our
work is also interesting in its own right, under the banner of
mathematical pharmacology, which is now a recognised
and growing field [51]. In [29], simple compartmental PK
models are proposed as a starting point for biomathematics
study and research. We propose a number of model per-
turbations and related mathematical directions beyond the
scope of the current work. Constructing exact solutions for
the TCM model relies on evaluation of the lower incom-
plete gamma function cðn; tÞ, which we have explored in
some detail. An assessment of the practicality of using the
analytical TCM results here versus numerical ODE solu-
tions would be useful. Incorporation of more efficient and
accurate approximation for cðn; tÞ, especially for parameter
estimation purposes, may be a valuable pursuit, as dis-
cussed in [1, 2, 7, 50]. We have proposed a thorough
practical and sturctural identifiability analysis of our TCM
(‘Transit compartments—smoothed delays, lag time and
data fitting (single-dose)’ and Appendix 2.3). A theoretical
comparison of the new TCM results and delay-differential
equation (DDE) modelling approaches (see [26, 38]) under
impulse train inputs is also warranted. Linear pharma-
cokinetics is studied in our work, and much of the solution
method relies on time-invariance of the PK parameters.
However, chronopharmacokinetics is an important phe-
nomenon that should be considered in PK ODE modelling
[8, 21, 52]. Extension of our models and methodology to
incorporate time-dependent parameters will be explored in
future, but may be limited to numerical computation.
Further, wider applicability of the TCM and EDRR
methods will be achieved by consideration of nonlinear
Michaelis-Menten elimination, which is discussed mathe-
matically in [49, 53]. Also, importantly, the PK models
here may be linked to pharmacodynamics (PD) models to
explore predicted drug responses; PD models are described
in detail in [20, 25, 43, 45].
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Appendix 1: multi-dosing solutions
Equi-dosing solutions are derived here. While the results
are well known for the one-compartment and two-com-
partment models, it is instructive to see their solutions
derived by Laplace Transform methods prior to deriving
the full transit compartment model solution. Further, the
steady-state solutions are vital for construction of EDRRs.
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Single compartment—equi-bolus dosing
The solution to the (M1,Beq) problem (see Table 1) can
easily be found using Laplace Transforms. We take the
Laplace Transform of the IVP, giving
and hence
AcðsÞ ¼ GBðsÞ
sþ ke :
ðA:1Þ
For dosing regimen (Beq), the Laplace Transform of the
dosing rate (2.3) is
GBðsÞ ¼ FD0
XM
j¼1
eðj1ÞTs; ðA:2Þ
and hence
AcðsÞ ¼ FD0
XM
j¼1
eðj1ÞTs
sþ ke :
Taking the inverse Laplace Transform, we find the solution
for the drug amount in the central compartment as
acðtÞ ¼ FD0
XM
j¼1
H

t  ðj 1ÞTeke

tðj1ÞT

; ðA:3Þ
where H is the Heaviside function. Since
tj ¼ t  ðj 1ÞT ¼ time since jth dose; ðA:4Þ
we can write
acðtÞ ¼ FD0
XM
j¼1
H

tjÞekeðtjÞ: ðA:5Þ
This solution may be written compactly without summa-
tion notation by considering, for example, the central
compartment drug level after the Mth dose, aMc ðtMÞ. The
finite geometric series resulting from (3.1) may be evalu-
ated to give
aMc ðtMÞ ¼ FD0
1 eMkeT
1 ekeT
 
eketM ; for 0 tM\T:
ðA:6Þ
We readily find the steady-state (T-periodic) behaviour by
letting M !1 in (A.6), giving
a1c ðt1Þ ¼
FD0
1 ekeT
 
eket1 ; for 0 t1\T: ðA:7Þ
For model (M1) with forcing (BeqL), superposition of (3.1)
with the solution corresponding to a single extra bolus
input of ðDL  D0Þ at time t ¼ 0 gives the solution for the
central compartment drug level as
acðtÞ ¼ F D0
XM
j¼1
H

tjÞeketj
 !
þ ðDL  D0Þeket
( )
:
ðA:8Þ
The central compartment drug level after the Mth dose,
aMc ðtMÞ, is then given by
aMc ðtMÞ ¼ F D0
1 eMkeT
1 ekeT
 
eketM


þðDL  D0ÞekeðtMþðM1ÞTÞ
o
:
ðA:9Þ
The loading dose effect is transient, so the steady-state
behaviour is unaffected by DL.
Single compartment—equi-infusion dosing
The solution to the (M1,Ieq) problem (see Table 1) can be
found using Laplace Transforms. Again, taking the Laplace
Transform of the IVP gives
and hence
AcðsÞ ¼ GIðsÞ
sþ ke :
ðA:10Þ
For dosing regimen (Ieq), the Laplace Transform of the
dosing rate (2.5) is
GIðsÞ ¼ Fkin
XM
j¼1
eðj1ÞTs  eððj1ÞTþtf Þs
s
; ðA:11Þ
and hence
AcðsÞ ¼ Fkin
XM
j¼1
eðj1ÞTs  eððj1ÞTþtf Þs
sðsþ keÞ :
Using the inverse Laplace Transform result [56]
L1 e
as
sðsþ keÞ

 
¼ Hðt  aÞð1 ekeðtaÞÞ;
we find the solution for the drug amount in the central
compartment as
acðtÞ ¼ Fkin
ke
XM
j¼1
HðtjÞð1 eketjÞ  Hðtj  tf Þð1 ekeðtjtf ÞÞ;
ðA:12Þ
where tj ¼ t  ðj 1ÞT . Again, a geometric series results,
and for 0 tM\T , we may express the drug level as
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aMc ðtMÞ ¼
Fkin
ke
ð1 eketM Þ  HðtM  tf Þð1 ekeðtMtf ÞÞ|fflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflffl{zfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflffl}
contributionfrom
Mthdose
8
<
:
þ ðeketf  1Þ e
MkeT  ekeT
ekeT  1
 
eketM
|fflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflffl{zfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflffl}
accumulation
9
>=
>;
:
ðA:13Þ
Letting M !1, we see that the steady-state (T-periodic)
level is given by
a1c ðt1Þ ¼
Fkin
ke
1 e
ketf  ekeT
1 ekeT e
ket1


Hðt1  tf Þð1 ekeðt1tf ÞÞ
o
; for 0 t1\T :
ðA:14Þ
Alternatively, we may express this as
a1c ðt1Þ ¼
Fkin
ke
ekeT  eketf
1 ekeT e
ket1 þ ekeðt1tf ÞHðt1tf Þ

 
:
ðA:15Þ
We note here that the standard result (see, e.g., [45]) for a
single continuous infusion is found by taking M ¼ 1 in
(3.6) to give
acðtÞ ¼ Fkin
ke
ð1 eketÞ: ðA:16Þ
Two compartments—equi-bolus dosing
With a view to generalising the model to multiple transit
compartment absorption, it is convenient to write the sys-
tem (M2) (from Table 1) in matrix form as
d
dt
x ¼ Bxþ g; xð0Þ ¼ 0; ðA:17aÞ
where
x ¼ abðtÞ
acðtÞ
 
; B ¼ ka 0
ka  ke
 
; g ¼ gBðtÞ
0
 
:
ðA:17bÞ
We solve the matrix ODE problem again using the method
of Laplace Transforms. Firstly, we have
sXðsÞ ¼ BXðsÞ þ GBðsÞ
0
 
;
which gives
XðsÞ ¼ ðsI  BÞ1 GBðsÞ
0
 
; ðA:18Þ
We readily find
ðsI  BÞ1 ¼ 1ðsþ kaÞðsþ keÞ
sþ ke 0
ka sþ ka
 
;
so that the Laplace Transform of the solution is
XðsÞ¼
GBðsÞ
sþka
GBðsÞ
ðsþkaÞðsþkeÞ
0
BB@
1
CCA¼
GBðsÞ
sþka
GBðsÞ
keka
1
sþka
1
sþke
 
0
BB@
1
CCA:
ðA:19Þ
Taking the inverse Laplace Transform, we find the solution
xðtÞ¼ abðtÞ
acðtÞ
 
¼
FD0
PM
j¼1HðtjÞekatj
ka
kekaFD0
XM
j¼1
HðtjÞ ekatjeketj
 
0
BB@
1
CCA :
ðA:20Þ
Transit compartments—equi-bolus dosing
The solution to the (Mt,Beq) problem (see Table 1) can be
found using Laplace Transforms. Taking the Laplace
Transform of the IVP (2.6) (with g1ðtÞ ¼ gBðtÞ) gives
ðsI  BÞXðsÞ ¼ GðsÞ; ðA:21Þ
where the only nonzero element of GðsÞ is G1ðsÞ ¼ GBðsÞ.
Now, ðsI  BÞ is lower bidiagnoal, given by:
ðsI  BÞ ¼
sþ k
k sþ k
 k sþ k
. .
. . .
.
 k sþ k
 k sþ ka
 ka sþ ke
0
BBBBBBBBBBBB@
1
CCCCCCCCCCCCA
:
ðA:22Þ
Hence (A.21) may be solved easily by a process of forward
substitution, or by noting that ðsI  BÞ1 is lower trian-
gular, given by:
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The Laplace Transform of the drug level aiðtÞ in the ith
transit compartment is then given by
AiðsÞ ¼ ðsI  BÞ11;i G1ðsÞ
¼ k
i1
ðsþ kÞi  GBðsÞ for i ¼ 1; . . .; n :
ðA:24Þ
The Laplace Transform of the drug level abðtÞ in the
absorption compartment is
AbðsÞ ¼ ðsI  BÞ11;nþ1 G1ðsÞ
¼ k
n
ðsþ kÞnðsþ kaÞ  GBðsÞ;
ðA:25Þ
while the transform of the drug level acðtÞ in the central
compartment is
AcðsÞ ¼ ðsI  BÞ11;nþ2 GBðsÞ
¼ k
nka
ðsþ kÞnðsþ kaÞðsþ keÞ  GBðsÞ;
ðA:26Þ
where, as before,
GBðsÞ ¼ FD0
XM
j¼1
eðj1ÞTs: ðA:27Þ
For the transit compartments, we find from (A.24) and
(A.27) that
aiðtÞ ¼ L1 AiðsÞf g ¼ FD0ki1L1
XM
j¼1
eðj1ÞTs
ðsþ kÞi
( )
:
Now, given that
L1 e
ðj1ÞTs
ðsþ kÞi
( )
¼ 1ði 1Þ!

t  ðj 1ÞTi1ek

tðj1ÞT

H

t  ðj 1ÞT;
¼ 1ði 1Þ! t
i1
j e
ktjHðtjÞ; where tj ¼ t  ðj 1ÞT ;
ðA:28Þ
we find that
aiðtÞ ¼ FD0ki1ði1Þ!
PM
j¼1 HðtjÞti1j ektj ; i ¼ 1; . . .; n:
ðA:29Þ
For the absorption compartment, we find from (A.25) and
(A.27) that
abðtÞ ¼ FD0knL1
XM
j¼1
eðj1ÞTs
ðsþ kÞn 
1
sþ ka
( )
: ðA:30Þ
Now,
L1 1
sþ ka

 
¼ ekatHðtÞ; ðA:31aÞ
and, from (A.28),
L1 e
ðj1ÞTs
ðsþ kÞn

 
¼ 1ðn 1Þ! t
n1
j e
ktjHðtjÞ: ðA:31bÞ
Setting sj ¼ s ðj 1ÞT , we readily compute the follow-
ing inverse transform as a convolution:
ðsI  BÞ1 ¼
1
sþ k
k
ðsþ kÞ2
1
sþ k
k2
ðsþ kÞ3
k
ðsþ kÞ2
1
sþ k
..
. ..
. ..
. . .
.
kn1
ðsþ kÞn
kn2
ðsþ kÞn1
kn3
ðsþ kÞn2   
1
sþ k
kn
ðsþ kÞnðsþ kaÞ
kn1
ðsþ kÞn1ðsþ kaÞ
kn2
ðsþ kÞn2ðsþ kaÞ
   kðsþ kÞðsþ kaÞ
1
sþ ka
knka
ðsþ kÞnðsþ kaÞðsþ keÞ
kn1ka
ðsþ kÞn1ðsþ kaÞðsþ keÞ
kn2ka
ðsþ kÞn2ðsþ kaÞðsþ keÞ
   kkaðsþ kÞðsþ kaÞðsþ keÞ
ka
ðsþ kaÞðsþ keÞ
1
sþ ke
0
BBBBBBBBBBBBBBBBBBBBBBBBBB@
1
CCCCCCCCCCCCCCCCCCCCCCCCCCA
:
ðA:23Þ
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L1 e
ðj1ÞTs
ðsþ kÞn 
1
sþ ka

 
¼
Z t
0
1
ðn 1Þ! s
n1
j e
ksjHðsjÞ
 
 ekaðtsÞHðt  sÞ
h i
ds;
¼ e
kat
ðn 1Þ!
Z t
0
HðsjÞsn1j eksj ekas ds;
¼ e
kat
ðn 1Þ!
Z tðj1ÞT
ðj1ÞT
HðsjÞsn1j eksj ekaðsjþðj1ÞTÞ dsj;
¼ e
kaðtðj1ÞTÞ
ðn 1Þ!
Z tðj1ÞT
ðj1ÞT
HðsjÞsn1j eðkkaÞsj dsj;
¼ HðtjÞe
katj
ðn 1Þ!
Z tj
0
sn1j e
ðkkaÞsj dsj:
ðA:31cÞ
For k 6¼ ka, we recognise the integral in the line above as
one related to the lower incomplete gamma function. In
particular, the lower incomplete gamma function c, defined
by (for positive integer n, see [3])
cðn; tÞ ¼
Z t
0
xn1ex dx ¼ ðn 1Þ! 1 et
Xn1
p¼0
tp
p!
 !
;
ðA:32Þ
has the following property (seen by making a change of
variables X ¼ ax):
Z t
0
xn1eax dx ¼ 1
an
cðn; atÞ: ðA:33Þ
So (A.31c) gives
L1 e
ðj1ÞTs
ðsþ kÞn 
1
sþ ka

 
¼ HðtjÞe
katj
ðn 1Þ!ðk  kaÞn cðn; ðk  kaÞtjÞ;
ðA:34Þ
and then (A.30) gives
abðtÞ ¼ FD0ðn1Þ! kkka
 	nPM
j¼1HðtjÞekatj c

n; ðk  kaÞtj

:
ðA:35Þ
For the central compartment, we find from (A.26) and
(A.27) that
acðtÞ ¼ FD0knkaL1
XM
j¼1
eðj1ÞTs
ðsþ kÞn 
1
ðsþ kaÞðsþ keÞ
( )
:
ðA:36Þ
Now, for ke 6¼ ka, we have
L1 1ðsþ kaÞðsþ keÞ

 
¼ HðtÞ
ke  ka e
kat  eket ;
ðA:37aÞ
L1 e
ðj1ÞTs
ðsþ kÞn 
1
ðsþ kaÞðsþ keÞ

 
¼
Z t
0
1
ðn 1Þ! s
n1
j e
ksjHðsjÞ
 
 Hðt  sÞ
ke  ka e
kaðtsÞ  ekeðtsÞ
 	 
ds;
¼ 1ðn 1Þ!ðke  kaÞZ t
0
HðsjÞsn1j eksj ekaðtsÞ  ekeðtsÞ
 	
ds;
¼ 1ðn 1Þ!
Z tðj1ÞT
ðj1ÞT
HðsjÞsn1j eksj ekatekasjþðj1ÞT

eketekesjþðj1ÞT
	
dsj;
¼ HðtjÞðn 1Þ!
Z tj
0
sn1j e
ksj
ekatekasjþðj1ÞT  eketekesjþðj1ÞT
 	
dsj;
¼ HðtjÞðn 1Þ! e
kaðtðj1ÞTÞ
Z tj
0
sn1j e
ðkkaÞsj dsj


 ekeðtðj1ÞTÞ
Z tj
0
sn1j e
ðkkeÞsj dsj

;
¼ HðtjÞðn 1Þ! e
katj
Z tj
0
sn1j e
ðkkaÞsj dsj


 eketj
Z tj
0
sn1j e
ðkkeÞsj dsj

:
ðA:37bÞ
Again, we write this result in terms of the lower incom-
plete gamma function, giving
L1 e
ðj1ÞTs
ðsþ kÞn 
1
ðsþ kaÞðsþ keÞ

 
¼ HðtjÞðn 1Þ! e
katjcðn; ðk  kaÞtÞ  eketjcðn; ðk  keÞtÞ
 
:
ðA:38Þ
Then (A.36) gives
acðtÞ ¼ FD0knkaðn1Þ!ðkekaÞ
PM
j¼1H tj
 
eka tj
ðkkaÞnc

n;ðkkaÞtj
 eketjðkkeÞnc

n;ðkkeÞtj
n o
:
ðA:39Þ
Steady-state behaviour
To complete the analysis (and with a view to constructing
EDRR’s), we require solutions for the steady-state time
course profiles. For each of the transit compartments
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(i ¼ 1; . . .; n), one approach is to solve the ODE for
0 t1\T , to give a solution parameterised by the initial
value a1i ð0Þ (where t1 ¼ 0 corresponds to the timing of
the bolus input to a1), then use periodicity to determine the
appropriate value of a1i ð0Þ. In the following, we use lower
case for the state variables and upper case for Laplace
Transforms. For clarity and illustration, we derive the
solutions for the first five transit compartments before
writing the solution for transit compartment n in general.
For compartment i ¼ 1, we have
da11 ðt1Þ
dt1
¼ ka11 ðt1Þ;
) sA11 ðsÞ  a11 ð0Þ ¼ kA11 ðsÞ;
) A11 ðsÞ ¼
a11 ð0Þ
sþ k ;
ðA:40aÞ
) a11 ðt1Þ ¼ a11 ð0Þekt1 : ðA:40bÞ
To determine a11 ð0Þ, we use the fact that there is periodic
bolus dose to this compartment:
a11 ð0Þ ¼ a11 ðTÞ þ FD0;
) a11 ð0Þ ¼ a11 ð0ÞekT þ FD0;
) a11 ð0Þ ¼
FD0
1 ekT :
ðA:40cÞ
Letting
/ ¼ kT ; ðA:41Þ
we write
a11 ð0Þ ¼
FD0
1 e/ : ðA:42Þ
For compartment i ¼ 2, we have
da12 ðt1Þ
dt1
¼ ka11 ðt1Þ  ka12 ðt1Þ;
) sA12 ðsÞ  a12 ð0Þ ¼ kA11 ðsÞ  kA12 ðsÞ;
) A12 ðsÞ ¼
a12 ð0Þ þ kA11 ðsÞ
sþ k ;
¼ a
1
2 ð0Þ
sþ k þ
ka11 ð0Þ
ðsþ kÞ2 ;
ðA:43aÞ
) a12 ðt1Þ ¼ a12 ð0Þ þ
ka11 ð0Þ
1!
t1
 
ekt1 : ðA:43bÞ
To determine a12 ð0Þ, we use periodicity (noting that for
i[ 1 the drug level is continuous):
a12 ð0Þ ¼ a12 ðTÞ;
) a12 ð0Þ ¼ a12 ð0ÞekT þ
ka11 ð0Þ
1!
TekT ;
¼ a12 ð0Þe/ þ
a11 ð0Þ
1!
/e/;
ðA:43cÞ
) a12 ð0Þ ¼
e/
1 e/ 
a11 ð0Þ
1!
/: ðA:43dÞ
Letting
b ¼ e
/
1 e/ ;
ðA:44Þ
we write
a12 ð0Þ ¼ a11 ð0Þ/
b
1!
: ðA:45Þ
For compartment i ¼ 3, we have
da13 ðt1Þ
dt1
¼ ka12 ðt1Þ  ka13 ðt1Þ;
) sA13 ðsÞ  a13 ð0Þ ¼ kA12 ðsÞ  kA13 ðsÞ;
) A13 ðsÞ ¼
a13 ð0Þ þ kA12 ðsÞ
sþ k ;
¼ a
1
3 ð0Þ
sþ k þ
ka12 ð0Þ
ðsþ kÞ2 þ
k2a11 ð0Þ
ðsþ kÞ3 ;
ðA:46aÞ
) a13 ðt1Þ ¼ a13 ð0Þ þ
ka12 ð0Þ
1!
t1 þ k
2a11 ð0Þ
2!
t21
 
ekt1 :
ðA:46bÞ
To determine a13 ð0Þ, we use periodicity:
a13 ð0Þ ¼ a13 ðTÞ;
) a13 ð0Þ ¼ a13 ð0ÞekT þ
ka12 ð0Þ
1!
TekT þ k
2a11 ð0Þ
2!
T2ekT ;
¼ a13 ð0Þe/ þ
a12 ð0Þ
1!
/e/ þ a
1
1 ð0Þ
2!
/2e/;
ðA:46cÞ
) a13 ð0Þ ¼ b
a12 ð0Þ
1!
/þ a
1
1 ð0Þ
2!
/2
 
ðA:46dÞ
¼ a11 ð0Þ/2
1
1!1!
b2 þ 1
2!
b
 
; (using (A.45)):
ðA:46eÞ
For compartment i ¼ 4, we have
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da14 ðt1Þ
dt1
¼ ka13 ðt1Þ  ka14 ðt1Þ;
) sA14 ðsÞ  a14 ð0Þ ¼ kA13 ðsÞ  kA14 ðsÞ;
) A14 ðsÞ ¼
a14 ð0Þ þ kA13 ðsÞ
sþ k ;
¼ a
1
4 ð0Þ
sþ k þ
ka13 ð0Þ
ðsþ kÞ2 þ
k2a12 ð0Þ
ðsþ kÞ3 þ
k3a11 ð0Þ
ðsþ kÞ4 ;
ðA:47aÞ
) a14 ðt1Þ ¼ a14 ð0Þ þ
ka13 ð0Þ
1!
t1

þ k
2a12 ð0Þ
2!
t21 þ
k3a11 ð0Þ
3!
t31

ekt1 :
ðA:47bÞ
To determine a14 ð0Þ, we use periodicity:
a14 ð0Þ ¼ a14 ðTÞ;
) a14 ð0Þ ¼ a14 ð0ÞekT þ
ka13 ð0Þ
1!
TekT
þ k
2a12 ð0Þ
2!
T2ekT þ k
3a11 ð0Þ
3!
T3ekT ;
¼ a14 ð0Þe/ þ
a13 ð0Þ
1!
/e/
þ a
1
2 ð0Þ
2!
/2e/ þ a
1
1 ð0Þ
3!
/3e/;
ðA:47cÞ
) a14 ð0Þ ¼ b
a13 ð0Þ
1!
/

þ a
1
2 ð0Þ
2!
/2 þ a
1
1 ð0Þ
3!
/2
 ðA:47dÞ
¼ a11 ð0Þ/3
1
1!1!1!
b3 þ 1
1!2!
þ 1
2!1!
 
b2 þ 1
3!
b
 
;
(using (A.45) and (A.46e)):
ðA:47eÞ
For compartment i ¼ 5, we have
da15 ðt1Þ
dt1
¼ ka14 ðt1Þ  ka15 ðt1Þ;
) sA15 ðsÞ  a15 ð0Þ ¼ kA14 ðsÞ  kA15 ðsÞ;
) A15 ðsÞ ¼
a15 ð0Þ þ kA14 ðsÞ
sþ k ;
¼ a
1
5 ð0Þ
sþ k þ
ka14 ð0Þ
ðsþ kÞ2
þ k
2a13 ð0Þ
ðsþ kÞ3 þ
k3a12 ð0Þ
ðsþ kÞ4 þ
k4a11 ð0Þ
ðsþ kÞ5 ;
ðA:48aÞ
) a15 ðt1Þ ¼ a15 ð0Þ þ
ka14 ð0Þ
1!
t1 þ k
2a13 ð0Þ
2!
t21

þ k
3a12 ð0Þ
3!
t31 þ
k4a11 ð0Þ
3!
t41

ekt1 :
ðA:48bÞ
To determine a15 ð0Þ, we use periodicity:
a15 ð0Þ ¼ a15 ðTÞ;
) a15 ð0Þ ¼ a15 ð0ÞekT þ
ka14 ð0Þ
1!
TekT þ k
2a13 ð0Þ
2!
T2ekT
þ k
3a12 ð0Þ
3!
T3ekT þ k
3a11 ð0Þ
4!
T4ekT ;
¼ a15 ð0Þe/ þ
a14 ð0Þ
1!
/e/
þ a
1
3 ð0Þ
2!
/2e/ þ a
1
2 ð0Þ
3!
/3e/ þ a
1
1 ð0Þ
4!
/4e/;
ðA:48cÞ
) a15 ð0Þ ¼ b
a14 ð0Þ
1!
/þ a
1
3 ð0Þ
2!
/2 þ a
1
2 ð0Þ
3!
/3 þ a
1
1 ð0Þ
4!
/4
 
ðA:48dÞ
¼ a11 ð0Þ/4
1
1!1!1!1!
b4 þ 1
1!1!2!
þ 1
1!2!1!
þ 1
2!1!1!
 
b3

þ 1
1!3!
þ 1
2!2!
þ 1
3!1!
 
b2
þ 1
4!
b

;
(using ðA:45Þ; ðA:46eÞ; ðA:47eÞÞ:
ðA:48eÞ
The process continues, and clearly, the solution for the
nth transit compartment at steady-state is given by
a1i ðt1Þ ¼ a1i ð0Þ þ
a1i1ð0Þ
1!
ðkt1Þ þ a
1
i2ð0Þ
2!
ðkt1Þ2

þ    þ a
1
1 ð0Þ
ði 1Þ! ðkt1Þ
i1

ekt1 ;
or
a1i ðt1Þ ¼
Pi1
p¼0
a1ipð0Þ
p! ðkt1Þp
 	
ekt1
; for i ¼ 1; . . .; n:
ðA:49aÞ
The coefficients aið0Þ (the steady-state dosing interval
initial values) may be found using
a11 ð0Þ ¼ FD01e/ : ðA:49bÞ
together with the recurrence relation (for i ¼ 2; . . .; n)
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aið0Þ¼b a
1
i1ð0Þ
1! /þ
a1i2ð0Þ
2! /
2þ a1i3ð0Þ
3! /
3þþ a11 ð0Þði1Þ!/i1
 	
¼ bPi1p¼1
a1ipð0Þ
p! /
p
:
ðA:49cÞ
The recurrence relation is clear when considering the
generalisation of (A.46d), (A.47d), (A.48d), etc. A closed-
form expression for aið0Þ is also possible by considering
the generalisation of (A.46e), (A.47e), (A.48e), etc. The
coefficient of bK in the expression for a1i ð0Þ is given by a
reciprocal factorial product related to partitioning and
permutations of a set of K positive integers which sum to
ði1Þ. These coefficients may be written in terms of the
Stirling number of the second kind [40], S, given by
Sðn; qÞ ¼ 1q!
Pq
p¼0ð1Þp
q
p
 
ðq pÞn
;
where
q
p
 
¼ q!
p!ðq pÞ! is the binomial coefficient;
ðA:49dÞ
and Sð0; 0Þ ¼ 1. Rewriting (A.42), (A.45), (A.46e),
(A.47e), (A.48e) so that the bracketed polynomials in b
have integer coefficients, and also continuing the process
up to the 10th transit compartment, we find that:
a11 ð0Þ ¼
FD0
1 e/ ;
a12 ð0Þ ¼
FD0
1 e/ /b;
a13 ð0Þ ¼
FD0
1 e/
/2
2!
2b2 þ b ;
a14 ð0Þ ¼
FD0
1 e/
/3
3!
6b3 þ 6b2 þ b ;
a15 ð0Þ ¼
FD0
1 e/
/4
4!
24b4 þ 36b3 þ 14b2 þ b ;
a16 ð0Þ ¼
FD0
1 e/
/5
5!
120b5 þ 240b4 þ 150b3 þ 30b2 þ b ;
a17 ð0Þ ¼
FD0
1 e/
/6
6!
720b6 þ 1800b5
þ1560b4 þ 540b3 þ 62b2 þ b;
a18 ð0Þ ¼
FD0
1 e/
/7
7!
5040b7

þ15120b6 þ 16800b5 þ 8400b4 þ 1806b3 þ 126b2 þ b;
a19 ð0Þ ¼
FD0
1 e/
/8
8!
40320b8 þ 141120b7
þ191520b6 þ 126000b5 þ 40824b4 þ 5796b3 þ 254b2 þ b;
a110ð0Þ ¼
FD0
1 e/
/9
9!
362880b9

þ1451520b8 þ 2328480b7 þ 1905120b6 þ 834120b5
þ186480b4 þ 18150b3 þ 510b2 þ b:
In terms of the Stirling number of the second kind, the
closed-form expression for a1i ð0Þ is
a1i ð0Þ ¼ FD01e/ /
i1
ði1Þ!
Pi1
p¼0 p!Sði 1; pÞbp ; for i ¼ 1; . . .; n:
ðA:49eÞ
For the absorption compartment, we have
da1b ðt1Þ
dt1
¼ ka1n ðt1Þ  kaa1b ðt1Þ;
) sA1b ðsÞ  a1b ð0Þ ¼ kA1n ðsÞ  kaA1b ðsÞ;
) A1b ðsÞ ¼
a1b ð0Þ þ kA1n ðsÞ
sþ ka ;
¼ a
1
b ð0Þ
sþ ka þ
k
sþ ka
Xn
p¼1
knpa1p ð0Þ
ðsþ kÞnpþ1 ;
ðA:50aÞ
) a1b ðt1Þ ¼ a1b ð0Þekat1
þ L1 k
sþ ka
Xn
p¼1
knpa1p ð0Þ
ðsþ kÞnpþ1
( )
:
ðA:50bÞ
Now, since
L1 1ðsþ kaÞðsþ kÞnpþ1
( )
¼ 1ðn pÞ!ðk  kaÞnpþ1
ekat1 cðn pþ 1; ðk  kaÞt1Þ;
ðA:50cÞ
we find that
a1b ðt1Þ ¼ a1b ð0Þ þ
Pn
p¼1
a1p ð0Þ
ðnpÞ!
k
kka
 	npþ1
cðn pþ 1; ðk  kaÞt1Þ
 
ekat1
:
ðA:50dÞ
To determine a1b ð0Þ, we use periodicity:
a1b ð0Þ ¼ a1b ðTÞ;
) a1b ð0Þ ¼ a1b ð0Þ þ
Xn
p¼1
a1p ð0Þ
ðn pÞ!
k
k  ka
 npþ1"
cðn pþ 1; ðk  kaÞTÞ
#
ekaT ;
ðA:50eÞ
so that
a1b ð0Þ ¼ ba
Pn
p¼1
a1p ð0Þ
ðnpÞ!
k
kka
 	npþ1
cðn pþ 1; ðk  kaÞTÞ
;
ðA:50fÞ
where
ba ¼ ekaT1ekaT : ðA:50gÞ
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Finally, for the central compartment, we have
da1c ðt1Þ
dt1
¼ kaa1b ðt1Þ  kea1c ðt1Þ;
) sA1c ðsÞ  a1c ð0Þ ¼ kaA1b ðsÞ  keA1c ðsÞ;
) A1c ðsÞ ¼
a1c ð0Þ þ kaA1b ðsÞ
sþ ke ;
¼ a
1
c ð0Þ
sþ ke þ
ka
sþ ke
a1b ð0Þ
sþ ka

þ k
sþ ka
Xn
p¼1
knpa1p ð0Þ
ðsþ kÞnpþ1
!
;
ðA:51aÞ
) a1c ðt1Þ ¼
a1c ð0Þ
sþ ke þ
ka
ðsþ keÞðsþ kaÞ a
1
b ð0Þ

þk
Xn
p¼1
knpa1p ð0Þ
ðsþ kÞnpþ1
!
:
ðA:51bÞ
Now, since
L1 1ðsþ kaÞðsþ keÞ

 
¼ Hðt1Þ
ke  ka e
kat1  eket1 ;
ðA:51cÞ
and
L1 1ðsþ kaÞðsþ keÞðsþ kÞnpþ1
( )
¼ 1ðn pÞ!ðka  keÞ
eket1
ðk  keÞnpþ1
cðn pþ 1; ðk  keÞt1Þ
 
 e
kat1
ðk  kaÞnpþ1
cðn pþ 1; ðk  kaÞt1Þ
!
;
ðA:51dÞ
we find that
a1c ðt1Þ¼a1c ð0Þeket1 þ
ka
kake
(
a1b ð0Þðeket1 ekat1Þ þ
Xn
p¼1
a1p ð0Þ
ðnpÞ!
k
kke
 npþ1
eket1 cðnpþ1;ðkkeÞt1Þ
"
k
kka
 npþ1
ekat1 cðnpþ1;ðkkaÞt1Þ
#)
:
ðA:51eÞ
To determine a1c ð0Þ, we use periodicity:
a1c ð0Þ ¼ a1c ðTÞ;
) a1c ð0Þ ¼ a1c ð0ÞekeT þ
ka
ka  ke

(
a1b ð0ÞðekeT  ekaTÞ þ
Xn
p¼1
a1p ð0Þ
ðn pÞ!
k
k  ke
 npþ1"
ekeT cðn pþ 1; ðk  keÞTÞ 
k
k  ka
 npþ1
ekaT cðn pþ 1; ðk  kaÞTÞ

)
;
ðA:51fÞ
so that
a1c ð0Þ ¼ bc 
(
a1b ð0ÞðekeT  ekaTÞ þ
Xn
p¼1
a1p ð0Þ
ðn pÞ!
k
k  ke
 npþ1
ekeT cðn pþ 1; ðk  keÞTÞ 
"
k
k  ka
 npþ1
ekaT cðn pþ 1; ðk  kaÞTÞ
#)
;
ðA:51gÞ
where
bc ¼ kaðkakeÞð1ekeT Þ : ðA:51hÞ
Computational evaluation of the lower incomplete gamma
function
Our preferred method for evaluating the lower incomplete
gamma function is using the built-in function gammainc
in MATLAB, which computes the normalised function
Pðn; tÞ ¼ cðn; tÞ
CðnÞ . In Fig. 16, we show a typical result
comparing run times and computed values of cðn; tÞ for a
given t and range of n, for five different methods. For
computations in MATLAB [35], it is clear that the quickest
method is using the built-in command gammainc. All
methods give values in agreement, except for the symbolic
computation of the sum in (3.17) for large n. This is due to
rounding and truncation errors introduced when evaluating
computed symbolic expressions. Hard-coding the expres-
sions in this sum results in the second shortest run time, but
this method is not practical for n[ 10. Use of the log-
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gamma function is an order of magnitude slower, but is still
much faster than employing a numerical integration
method. We conclude that built-in functions, either eval-
uating cðn; tÞ directly or via the log-gamma and distribution
functions, represent a practical approach to evaluating
cðn; tÞ. More efficient methods involving series and con-
tinued fraction expansions may be investigated
[1, 2, 17, 41, 50], but are beyond our scope here.
Appendix 2: time course results
Single continuous infusion as limit of IV equi-
bolus dosing
Recalling the IV equi-dosing result (3.2), we consider
dosing regimens which keep the ratio D0T fixed, and let
T ! 0. That is, consider a fixed dosing rate R ¼ D0T . Now
consider the drug level at the end of the Mth dosing
interval:
aMc ðTÞ ¼ FD0
1 eMkeT
1 ekeT e
keT ¼ FRT 1 e
MkeT
1 ekeT e
keT :
Suppose that by the end of the Mth dosing interval the total
Fig. 16 Run time (desktop PC, Intel(R) Core(TM) i5-9400, 2.9GHz)
and value for different implementations of the lower incomplete
gamma function cðn; tÞ in MATLAB. The methods include (i) use of
built-in function gammainc, (ii) numerical evaluation of the integral
in (3.17) using integral command, (iii) hard-coding the sum in the
final term of (3.17) for n ¼ 1; . . .; 10, (iv) use of MATLAB’s
Symbolic Toolbox to expand the sum, (v) use of built-in functions
gammaln and gamcdf for log-gamma and cumulative distribution
functions for the calculation in (3.32). A typical result is shown,
taking t ¼ 2. Similar results are seen for a range of t values. The
average evaluation time in seconds is found using MATLAB’s
timeit command. a Evaluation times for different methods, for
n ¼ 1; . . .; 10. b Evaluation times for different methods, for
n ¼ 1; . . .; 40. c Computed values for different methods, for
n ¼ 1; . . .; 10. d Computed values for different methods, for
n ¼ 1; . . .; 40
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time since the first dose is tend (fixed constant). Then
tend ¼ MT , and so
acðtendÞ ¼ aMc ðTÞ ¼ FR
1 eketend
1 ekeT Te
keT :
Then taking infinitesimally small dosing interval (and so an
infinitesimal dose), our result becomes
acðtendÞ ! lim
T!0
FRð1 eketendÞ Te
keT
1 ekeT :
Now, using l’Hopital’s Rule, we see that
acðtendÞ ! FRð1 eketend Þ lim
T!0
ekeTð1 keTÞ
keekeT
:
Thus, as T ! 0, we have
acðtendÞ ! FRð1 ketendÞ  1
ke
¼ FR
ke
ð1 eketend Þ:
Now, if R ¼ D0T ¼ kin, then
acðtendÞ ! Fkin
ke
ð1 eketend Þ; ðB:1Þ
which is equivalent to the continuous infusion solution
(4.1). 
Two-compartment oral equi-bolus dosing
Here, we note some properties of the two-compartment
equi-bolus dosing solutions (3.10) and (3.11). Firstly, the
minimum drug level on the nth dosing interval is given by
ancð0Þ, while for a local maximum (a peak level) in the time
course for ancðtnÞ at tn ¼ tn, we need anc 0ðtnÞ ¼ 0. We find,
by using (3.10), that:
tn ¼
1
ka  ke log
ka
ke
1 enkaT
1 ekaT
1 ekeT
1 enkeT
 
: ðB:2Þ
If 0\tn\T , then there is a peak blood drug level in the nth
dosing interval, given by
Fig. 17 Non-identifiability of k and ka for transit compartment model
with n ¼ 1. Solutions for a single bolus dose with FD0 ¼ 1 are
shown, for two parameter sets. Parameter set 1 has
ðk; ka; keÞ ¼ ð0:2; 1; 0:1Þ, and parameter set 2 has
ðk; ka; keÞ ¼ ð1; 0:2; 0:1Þ. The two parameter sets lead to identical
time course for the observed output acðtÞ, via different time courses
for a1ðtÞ and abðtÞ
Fig. 18 Parameter fitting for transit compartment model with n ¼ 10.
Pseudo-data (time courses of acðtÞ) are generated by simulating with
base parameter values k ¼ 12:76 h1, ka ¼ 9:11 h1, ke ¼ 0:96 h1,
F ¼ 0:69, and a single bolus dose of 3.5 mg. a No noise is added to
the simulated time course, so the data are ‘‘perfect’’. The four
parameter values are estimated perfectly. b Randomly generated noise
(with an upper bound of 10% of the simulated peak value) is added to
create noisy data. The parameter estimates returned are
k ¼ 13:45 h1, ka ¼ 7:46 h1, ke ¼ 0:92 h1, F ¼ 0:67
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Fig. 19 Equi-dosing time courses for transit compartment model
(Mt,Beq), showing transit, absorption and central compartment drug
levels. Simulated time courses (Mt,Beq) for n ¼ 10 transit compart-
ments with MTT ¼ 0:7837h. Here, F ¼ 0:69, ke=0.96 h1
ka=9.11 h
1, k=12.76 h1. Equi-dosing regimen has D0=3.5 mg,
T=3h. For validation, we show results from analytical solution and a
numerically computed solution. The dosing interval average at
steady-state is indicated. Also, the steady-state profile is shown for
each compartment
Fig. 20 Equi-dosing time courses for transit compartment model
(Mt,Beq), showing transit, absorption and central compartment drug
levels. Simulated time courses (Mt,Beq) for n ¼ 10 transit compart-
ments with MTT ¼ 0:7837h. Here, F ¼ 0:69, ke=0.96 h1
ka=9.11 h
1, k=3.19 h1. Equi-dosing regimen has D0=3.5 mg, T=3
h. For validation, we show results from analytical solution and a
numerically computed solution. The dosing interval average at
steady-state is indicated. Also, the steady-state profile is shown for
each compartment
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anc ;max ¼ anc tn
 
¼ FD0 ke
ka
 ke 1 ekaT
1 enkaT
 ke 1 enkeT
1 ekeT
 ka( ) 1kake
:
ðB:3Þ
So we may write the maximum and minimum values of anc
on [0, T] as:
anc ;min¼ancð0Þ ¼ FD0
ka
kake
1enkeT
1ekeT 
1enkaT
1ekaT

 
;
ðB:4Þ
anc ;max ¼ anc minðtn; TÞ
 
; (using (B.2)) : ðB:5Þ
At steady-state, a local maximum in the time course is
ensured, occurring at
t1 ¼
1
ka  ke log
ka
ke
1 ekeT
1 ekaT
 
: ðB:6Þ
The steady-state minimum and maximum drug levels are
then given by
a1c ;min¼a1c ð0Þ ¼ FD0
ka
kake
1
1ekeT 
1
1ekaT

 
;
ðB:7Þ
a1c ;max ¼ a1c t1
  ¼ FD0 ke
ka
 ke 1 ekaT ke
1 ekeTð Þka
( ) 1
kake
:
ðB:8Þ
Transit compartment parameter identifiability
In Fig. 17, we show time courses for a transit compartment
model with n ¼ 1 with a single bolus dose. Non-identifia-
bility of k and ka is clear, due to the flip-flop phenomenon
discussed in ‘Transit compartments—smoothed delays, lag
time and data fitting (single-dose)’. For our transit com-
partment model, this problem is unique to n ¼ 1, and no
such issues are seen with n[ 1. In Fig. 18, we plot a
typical parameter estimation result for n ¼ 10 compart-
ments, using the method described in ‘Transit compart-
ments—smoothed delays, lag time and data fitting (single-
dose)’. With ‘‘perfect’’ pseudo-data, we see the base
parameter set being recovered exactly, and with noisy
pseudo-data, the parameter estimates are in good agree-
ment with the base set. A formal structural and practical
identifiability analysis is proposed as future work, and will
use transfer functions and other methods described in [13].
Transit compartment equi-bolus dosing
In Figs. 19–20, we show time course results for a transit
compartment model under multi-dosing input (Mt,Beq),
using parameters taken from the fitted data in Fig. 5. Each
figure shows the analytical results for drug levels in a
number of transit compartments, with n ¼ 10 transit com-
partments in total. The absorption and central compart-
ments are also shown. For validation, results from a
numerical ODE solver are also shown. For tracking the
approach to steady-state, we mark the steady-state profile
and dosing interval average for each compartment plotted.
For each of the transit compartments, the steady-state
dosing interval average may be computed, for example,
from (2.6) by integrating each of the compartment ODEs in
turn. We find the transit compartment averages to be
a1i ½0;T  ¼
FD0
kT
; for i ¼ 1; . . .; n : ðB:9Þ
Similarly, for the absorption and central compartments, we
find
a1b ½0;T  ¼
FD0
kaT
; a1c ½0;T  ¼
FD0
keT
: ðB:10Þ
In both figures, we observe the delay effect, as the peak
drug levels appear later further through the transit cascade.
In Fig. 19, the transit rate constant k is taken from the
earlier data fitting, and the system almost reaches steady-
state by the second dosing interval. In Fig. 20, we take
k four-fold lower, which increases the smoothed delay, and
hence delays the approach to steady-state. In this case, the
delay effect is more evident throughout the transit cascade.
Fig. 21 Three-dimensional ðT ;D0;DLÞ equi-dosing regimen region
(EDRR) for IV dosing with loading dose, with F ¼ 1, ke=0.0692 h1,
and hypothetical minimum effective and maximum safe drug levels
Dme ¼ 300 mg and DMS ¼ 1000 mg, as in Fig. 13. Projection onto
ðT;D0Þ-plane (the shadow) is the standard two-parameter full-petal
EDRR for steady-state conditions for oral dosing. The shadow of any
chopped petal slice (DL ¼ constant) through the three-dimensional
EDRR is contained within this
Journal of Pharmacokinetics and Pharmacodynamics
123
Appendix 3: equi-dosing regimen region
for IV equi-bolus dosing with loading dose
In Fig. 21, we show a computed example EDRR for the
three-parameter ðT;D0;DLÞ regimen including loading
dose. Cross sections of fixed DL through the EDRR are
chopped petals, while the EDRR shadow in the ðT ;D0Þ-
plane is the full petal EDRR for the steady-state.
References
1. Abergel R, Moisan L (2016) Fast and accurate evaluation of a
generalized incomplete gamma function. HAL Archives hal-
01329669v2
2. Amore P (2005) Asymptotic and exact series representations for
the incomplete gamma function. EPL (Europhys Lett) 71:1–7
3. Arfken GB, Weber HJ (1999) Mathematical methods for
physicists
4. Bauer RJ (2019) Nonmem users guide: introduction to nonmem
7.4. 3, icon plc gaithersburg Maryland
5. Beguerisse-Dı´az M, Desikan R, Barahona M (2016) Linear
models of activation cascades: analytical solutions and coarse-
graining of delayed signal transduction. J R Soc Interface. https://
doi.org/10.1098/rsif.2016.0409
6. Bertrand J, Mentre´ F (2008) Mathematical expressions of the
pharmacokinetic and pharmacodynamic models implemented in
the monolix software. Paris Diderot University, Paris
7. Blahak U (2010) Efficient approximation of the incomplete
gamma function for use in cloud model applications. Geosci
Model Dev 3(2):329
8. Bordyugov G, Westermark PO, Korencˇicˇ A, Bernard S, Herzel H
(2013) Mathematical modeling in chronobiology. Circadian
clocks. Springer, New York, pp 335–357
9. Boyce WE (2010) Differential equations: an introduction to
modern methods and applications. Wiley, London
10. Brocks DR, Mehvar R (2010) Rate and extent of drug accumu-
lation after multiple dosing revisited. Clin Pharmacokinet
49(7):421–438
11. Burghes DN, Huntley ID, McDonald JJ (1982) A course in
mathematical modelling. Applying mathematics. Ellis Horwood,
Amsterdam
12. Di Muria M, Lamberti G, Titomanlio G (2010) Physiologically
based pharmacokinetics: a simple, all purpose model. Ind Eng
Chem Res 49(6):2969–2978
13. DiStefano J (2015) Dynamic systems biology modeling and
simulation. Academic Press, Cambridge
14. Dunnington K, Benrimoh N, Brandquist C, Cardillo-Marricco N,
Di Spirito M, Grenier J (2018) Application of pharmacokinetics
in early drug development. Pharmacokinetics and adverse effects
of drugs-mechanisms and risks factors. IntechOpenIntechOpen,
London
15. Felmlee MA, Morris ME, Mager DE (2012) Mechanism-based
pharmacodynamic modeling. Computational Toxicology.
Springer, New York, pp 583–600
16. Gabrielsson, Andersson K, Tobin G, Ingvast-Larsson C, Jirstrand
Mats (2014) Maxsim2-real-time interactive simulations for
computer-assisted teaching of pharmacokinetics and pharmaco-
dynamics. Comput Methods Programs Biomed 113(3):815–829
17. Gautschi W (1979) A computational procedure for incomplete
gamma functions. ACM Trans Math Softw (TOMS)
5(4):466–481
18. Germani M, Del Bene F, Rocchetti M, Van Der Graaf PH (2013)
A4S: a user-friendly graphical tool for pharmacokinetic and
pharmacodynamic (PK/PD) simulation. Comput Methods Pro-
grams Biomed 110(2):203–214
19. Gibaldi M, Perrier D (1982) Pharmacokinetics. Markel Dekker
Inc., New York
20. Gieschke R, Serafin D (2013) Development of innovative drugs
via modeling with matlab. Springer, New York
21. Godfrey KR (1988) A mathematical model for time-varying
pharmacokinetics. IFAC Proc Vol 21(1):103–108
22. Iraj H, Anita G, Yadav DB, Sukumaran S, Ramanujan S, Paxson
R, Gadkar K (2018) gpkpdsim: a simbiology-based gui appli-
cation for pkpd modeling in drug development. J Pharmacokinet
Pharmacodynam 45(2):259–275
23. Shuhua H, Dunlavey M, Guzy S, Teuscher N (2018) A distributed
delay approach for modeling delayed outcomes in pharmacoki-
netics and pharmacodynamics studies. J Pharmacokinet Phar-
macodynam 45(2):285–308
24. Jones DS, Plank M, Sleeman BD (2009) Differential equations
and mathematical biology. CRC Press, Boca Raton
25. Kallen A (2007) Computational pharmacokinetics. Chapman and
Hall/CRC, Boca Raton
26. Gilbert K, Wojciech K, Pe´rez-Ruixo JJ, Schropp J (2014)
Modeling of delays in pkpd: classical approaches and a tutorial
for delay differential equations. J Pharmacokinet Pharmacody-
nam 41(4):291–318
27. Koch G, Schropp J (2012) General relationship between transit
compartments and lifespan models. J Pharmacokinet Pharmaco-
dynam 39(4):343–355
28. Koch G, Wagner T, Plater-Zyberk C, Lahu G, Schropp Johannes
(2012) Multi-response model for rheumatoid arthritis based on
delay differential equations in collagen-induced arthritic mice
treated with an anti-gm-csf antibody. J Pharmacokinet Pharma-
codynam 39(1):55–65
29. Koch-Noble GA (2011) Drugs in the classroom: uusing phar-
macokinetics to introduce biomathematical modeling. Math
Model Nat Phenom 6(6):227–244
30. Krzyzanski W (2011) Interpretation of transit compartments
pharmacodynamic models as lifespan based indirect response
models. J Pharmacokinet Pharmacodynam 38(2):179–204
31. Lavielle M, Team l (2014) Mlxtran, the model coding language
for monolix, Tech. report, Technical report, INRIA Saclay &
Lixoft
32. Lawrence XY, Amidon GL (1999) A compartmental absorption
and transit model for estimating oral drug absorption. Int J Pharm
186(2):119–125
33. Yu Lawrence X, Crison JR, Amidon GL (1996) Compartmental
transit and dispersion model analysis of small intestinal transit
flow in humans. Int J Pharm 140(1):111–118
34. Lyons MA (2018) Modeling and simulation of pretomanid
pharmacokinetics in pulmonary tuberculosis patients. Antimi-
crobial Agents Chemother. https://doi.org/10.1128/AAC.02625-
16
35. MATLAB (2020) The MathWorks Inc., Natick, MA
36. Mehvar R (1998) Pharmacokinetic-based design and modification
of dosage regimens. Am J Pharm Educ 62:189–95
37. Microsoft Corporation, Microsoft excel
38. Mocek WT, Rudnicki R, Voit EO (2005) Approximation of
delays in biochemical systems. Math Biosci 198(2):190–216
39. Musuamba FT, Manolis E, Holford N, Cheung SYA, Friberg LE,
Ogungbenro K, Posch M, Yates JWT, Berry S, Thomas N et al
(2017) Advanced methods for dose and regimen finding during
drug development: summary of the ema/efpia workshop on dose
finding (london 4–5 december 2014). CPT Pharmacometr Syst
Pharmacol 6(7):418–429
Journal of Pharmacokinetics and Pharmacodynamics
123
40. Olver Frank WJ, Lozier DW, Boisvert RF, Clark CW (2010) Nist
handbook of mathematical functions hardback and cd-rom.
Cambridge University Press, Cambridge
41. Press WH, Teukolsky SA, Vetterling WT, Flannery BP (2007)
Numerical recipes 3rd edition: the art of scientific computing.
Cambridge University Press, Cambridge
42. Ankit Rohatgi, Webplotdigitizer (2011)
43. Rosenbaum SE (2012) Basic pharmacokinetics and pharmaco-
dynamics: an integrated textbook and computer simulations.
Wiley, London
44. Savic RM, Jonker DM, Kerbusch T, Karlsson MO (2007)
Implementation of a transit compartment model for describing
drug absorption in pharmacokinetic studies. J Pharmacokinet
Pharmacodynam 34(5):711–726
45. Shargel L, Andrew BC, Wu-Pong S (2012) Applied biopharma-
ceutics and pharmacokinetics, 6th edn. Appleton & Lange
Reviews/McGraw-Hill, New York
46. Shen J, Boeckmann A, Vick A (2012) Implementation of dose
superimposition to introduce multiple doses for a mathematical
absorption model (transit compartment model). J Pharmacokinet
Pharmacodynam 39(3):251–262
47. Sun Y-N, Jusko WJ (1998) Transit compartments versus gamma
distribution function to model signal transduction processes in
pharmacodynamics. J Pharm Sci 87(6):732–737
48. Swat MJ, Wimalaratne S, Kristensen NR, Yvon F, Moodie S, Le
Novere N (2015) Pharmacometrics markup language (pharmml),
Language Specification for Version 10, no. 0.6
49. Tang S, Xiao Y (2007) One-compartment model with michaelis-
menten elimination kinetics and therapeutic window: an analyt-
ical approach. J Pharmacokinet Pharmacodynam 34(6):807–827
50. Temme NM (2007) Numerical aspects of special functions. Acta
Numer doi. https://doi.org/10.1137/1.9780898717822
51. van der Graaf PH, Benson N, Peletier LA (2016) Topics in
mathematical pharmacology. J Dynam Differ Equ
28(3–4):1337–1356
52. Ve´ronneau-Veilleux F, Be´lair J (2017) Modeling circadian fluc-
tuations of pharmacokinetic parameters. Math Model Nat Phe-
nom 12(5):146–161
53. Xiaotian, Nekka F, Li J (2019) Analytical solution and exposure
analysis of a pharmacokinetic model with simultaneous elimi-
nation pathways and endogenous production: The case of mul-
tiple dosing administration. Bull Math Biol 81(9):3436–3459
54. Yang J, Mager DE, Straubinger RM (2010) Comparison of two
pharmacodynamic transduction models for the analysis of tumor
therapeutic responses in model systems. AAPS J 12(1):1–10
55. Yates JWT (2008) Mathematical properties and parameter esti-
mation for transit compartment pharmacodynamic models. Eur J
Pharm Sci 34(2–3):104–109
56. Zill DG, Wright WS (2012) Differential equations with bound-
ary-value problems. Cengage Learning, Boston
Publisher’s Note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
Journal of Pharmacokinetics and Pharmacodynamics
123
